

Publications Involving CDRI Authors or Using CDRI Data
Jan 2023–Aug 2025

Idaho-specific reports

1. **Morawski BM, Johnson CJ, Rycroft RK.** Cancer in Idaho — 2023, Preliminary Data. Boise, ID: Cancer Data Registry of Idaho; September 2025.
2. **Johnson CJ, Morawski BM, Rycroft RK.** Pediatric Cancer in Idaho, 2013–2022. Boise, ID: Cancer Data Registry of Idaho; July 2025.
3. **Johnson CJ, Morawski BM, Rycroft RK.** Cancer in Idaho — 2022. Boise, ID: Cancer Data Registry of Idaho; December 2024.
4. **Johnson CJ, Morawski BM, Rycroft RK.** Cancer County Profiles: 2017–2021 Incidence Years. Boise, ID: Cancer Data Registry of Idaho; June 2024.
5. **Johnson CJ, Morawski BM, Rycroft RK.** Pediatric Cancer in Idaho, 2012–2021. Boise, ID: Cancer Data Registry of Idaho; May 2024.
6. **Johnson CJ, Morawski BM, Rycroft RK.** Cancer in Idaho — 2022, Preliminary Data. Boise, ID: Cancer Data Registry of Idaho; 2024.
7. **Johnson CJ, Morawski BM, Rycroft RK.** Cancer in Idaho — 2021. Boise, ID: Cancer Data Registry of Idaho; December 2023.
8. **Morawski BM.** Leukemia in Idaho — 2000–2020. Boise, ID: Cancer Data Registry of Idaho; July 2023.
9. **Johnson CJ, Morawski BM, Rycroft RK.** Pediatric Cancer in Idaho, 2011–2020. Boise, ID: Cancer Data Registry of Idaho; June 2023.
10. **Johnson CJ, Morawski BM, Rycroft RK.** Cancer County Profiles, 2016–2020 Incidence Years. Boise, ID: Cancer Data Registry of Idaho; March 2023.
11. **Johnson CJ, Morawski BM, Rycroft RK.** Cancer in Idaho — 2021, Preliminary Data. Boise, ID: Cancer Data Registry of Idaho; 2023.

Peer-reviewed publications

12. Yu M, Joe N, Sherman RL, **Johnson CJ**, Negoita S, Scoppa S, Gibson JT, Cronin KA. The impact of the 1997 Office of Management and Budget standards for collecting multiracial data on the assessment of race-specific cancer rates of incidence and mortality in the United States. *Cancer*. 2025 Aug 1;131(15):e35930. doi: 10.1002/cncr.35930. PMID: 40685849; PMCID: PMC12277864.
13. Liu Q, Wang Q, Wang K, Han H, Wang M, Wang J, Song M, Giovannucci E. Risk of atherosclerotic cardiovascular disease after cancer diagnosis: findings from 3 prospective cohort studies. *J Natl Cancer Inst*. 2025 Aug 1;117(8):1707-1716.
14. Liu Y, Song M, Giovannucci EL, Platz EA. Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study. *J Natl Cancer Inst*. 2025 Aug 1;117(8):1733-1737.
15. Jackson SS, Pfeiffer RM, Gardner E, Hsieh MC, Insaf T, Lynch CF, **Morawski BM**, Wang S, Yu KJ, Engels EA. Sex differences in cancer mortality among solid organ transplant recipients. *Int J Cancer*. 2025. 157(3), 427-435.
16. Chen N, McGee EE, Nethery RC, Mucci LA, Dickerman BA. Guideline-based physical activity and health-related quality of life among prostate cancer survivors: a target trial emulation in the Health Professionals Follow-up Study. *Am J Epidemiol*. 2025 Jun 4. Epub 2025 Jun 4.
17. McGee EE, Hernán MA, Giovannucci E, Mucci LA, Chiu YH, Eliassen AH, Dickerman BA. Estimating the Effects of Lifestyle Interventions on Mortality Among Cancer Survivors: A Methodologic Framework. *Epidemiology*. 2025 Sep 1;36(5):705-718. Epub 2025 Jun 3.

18. Lee DH, Rezende LFM, Ferrari G, Zhang Y, Wang QL, Oh H, Keum N, Hu J, Jeon JY, Mucci LA, Giovannucci EL. Postdiagnosis physical activity and dietary inflammatory and insulinemic potential with overall survival in men with nonmetastatic prostate cancer. *Eur J Epidemiol.* 2025 Jun;40(6):669-679. Epub 2025 May 28.
19. Watling CZ, Petrick JL, Graubard BI, Zhang X, Barnett MJ, Buring JE, Chen Y, Eliassen AH, Gaziano M, Kang JH, Koshiol J, Huang WY, Lee IM, Moore SC, Mucci LA, Neuhaus ML, Newton CC, Palmer JR, Rosenberg L, Sesso HD, Shrubsole M, Tinker L, Triplette M, Um CY, Visvanathan K, Wactawski-Wende J, Willett W, Wu F, Zheng W, Hofmann J, Purdue MP, Campbell PT, Barupal D, McGlynn KA. Circulating per- and polyfluoroalkyl substances and liver cancer risk: a nested case-control analysis of individual participant data from 12 prospective cohorts. *Environ Health Perspect.* 2025 May 21. Epub 2025 May 21.
20. Hong YD, Howlader N, Noone AM, Mariotto AB. Assessing the effect of the COVID-19 pandemic on 1-year cancer survival in the United States. *J Natl Cancer Inst.* 2025 May 1;117(5):1064-1068.
21. Li X, Hur J, Zhang Y, Song M, Smith-Warner SA, Liang L, Mukamal KJ, Rimm EB, Giovannucci EL. Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women. *J Natl Cancer Inst.* 2025 May 1;117(5):971-979.
22. Naudin S, Wang M, Dimou N, Ebrahimi E, Genkinger J, Adami HO, Albanes D, Babic A, Barnett M, Bogumil D, Cai H, Chen C, Eliassen AH, Freudenheim JL, Gierach G, Giovannucci EL, Gunter MJ, Håkansson N, Hirabayashi M, Hou T, Huang BZ, Huang WY, Jayasekara H, Jones ME, Katzke VA, Koh WP, Lacey JV, Lagerros YT, Larsson SC, Liao LM, Lo K, Lofffield E, MacInnis RJ, Männistö S, McCullough ML, Miller A, Milne RL, Moore SC, Mucci LA, Neuhaus ML, Patel AV, Platz EA, Prizment A, Robien K, Rohan TE, Sacerdote C, Sandin S, Sawada N, Schoemaker M, Shu XO, Sinha R, Snetselaar L, Stampfer MJ, Stolzenberg-Solomon R, Thomson CA, Tjønneland A, Um CY, van den Brandt PA, Visvanathan K, Wang SS, Wang R, Weiderpass E, Weinstein SJ, White E, Willett W, Wosik A, Wolpin BM, Yaun SS, Yuan C, Yuan JM, Zheng W, Brennan P, Smith-Warner SA, Ferrari P. Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America. *PLoS Med.* 2025 May 20;22(5):e1004590. doi: 10.1371/journal.pmed.1004590. eCollection 2025 May.
23. Roberts AL, Townsend MK, Chibnik LB, Kubzansky LD, Tworoger SS. Timing of depression in relation to risk of ovarian cancer. *J Natl Cancer Inst.* 2025 May 1;117(5):989-996.
24. Freda PU, Bruce JN, Jin Z, Kostadinov J, Khandji AG, Cremers S, Post KD. Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly. *J Clin Endocrinol Metab.* 2025 Apr 22;110(5):1247-1257.
25. Romanos-Nanclares A, Schernhammer E, Willett WC, Holmes MD, Chen WY, Eliassen AH. Consumption of aspartame and risk of breast cancer in the Nurses' Health Studies. *J Natl Cancer Inst.* 2025 Apr 1;117(4):795-800.
26. Howlader N, Chen HS, Noone AM, Miller D, Byrne J, Negoita S, Cronin KA, Mariotto AB. Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline. *J Natl Cancer Inst.* 2025 Mar 1;117(3):507-510.
27. Sullivan M, Lei X, Karuturi M, Malinowski C, Giordano SH, Chavez-MacGregor M. Use of adjuvant capecitabine in older patients with early-stage triple-negative breast cancer. *Breast Cancer Res Treat.* 2025 May;211(1):213-221. Epub 2025 Feb 28.
28. Assad A, Incesu RB, Morra S, Scheipner L, Baudo A, Siech C, De Angelis M, Tian Z, Ahyai S, Longo N, Chun FKH, Shariat SF, Tilki D, Briganti A, Saad F, Karakiewicz PI. The Effect of Adrenalectomy on Overall Survival in Metastatic Adrenocortical Carcinoma. *J Clin Endocrinol Metab.* 2025 Feb 18;110(3):748-757.
29. Barnard ME, Poole EM, Huang T, Sood AK, Kubzansky LD, Tworoger SS. Caregiver burden and risk of epithelial ovarian cancer in the Nurses' Health Studies. *Am J Epidemiol.* 2025 Feb 5;194(2):362-369.

30. Guo F, McGee EE, Chiu YH, Giovannucci E, Mucci LA, Dickerman BA. Evaluating recommendation-based dietary and physical activity strategies for prostate cancer prevention: a target trial emulation in the Health Professionals Follow-up Study. *Am J Epidemiol.* 2025 Feb 5;194(2):449-459.
31. El Khoury CJ, Freedland SJ, Gandhi K, Keith SW, Nikita N, Shaver A, Sharma S, Kelly WMK, Lu-Yao G. Disparities in the utilization of magnetic resonance imaging for prostate cancer detection: a population-based study. *J Natl Cancer Inst.* 2025 Feb 1;117(2):270-278.
32. Rodriguez VE, Tanjasiri SP, Ro A, Hoyt MA, Bristow RE, LeBrón AMW. Trends in endometrial cancer incidence in the United States by race/ethnicity and age of onset from 2000 to 2019. *Am J Epidemiol.* 2025 Jan 8;194(1):103-113.
33. Emile SH, Horesh N, Garoufalia Z, Gefen R, Dourado J, Wexner SD. A SEER Registry-Based Analysis of Pediatric Colorectal Adenocarcinomas. *JAMA Oncol.* 2025 Jan 1;11(1):71-73.
34. Liu Z, Hong P, He J, Li Z, Wu J, Qiu L, Zhao Z, Lu J. Favorable prostate-specific antigen levels correlate with a worse prognosis in high-grade prostate cancer: a population-based analysis. *Int J Surg.* 2025 Jan 1;111(1):807-817.
35. Tuminello S, Turner WM, Untalan M, Ivic-Pavlicic T, Flores R, Taioli E. Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake. *J Natl Cancer Inst.* 2025 Jan 1;117(1):112-119.
36. Leslie Salewon M, Pathak R, Dooley WC, Squires RA, Rui H, Chervoneva I, Tanaka T. Surgical delay-associated mortality risk varies by subtype in loco-regional breast cancer patients in SEER-Medicare. *Breast Cancer Res.* 2024 Dec 30;26(1):191.
37. Siech C, de Angelis M, Jannello LMI, Di Bello F, Rodriguez Peñaranda N, Goyal JA, Tian Z, Saad F, Shariat SF, Puliatti S, Longo N, de Cobelli O, Briganti A, Wenzel M, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Life expectancy in rare histological prostate cancer subtypes. *Int J Cancer.* 2025 Jun 15;156(12):2311-2319. Epub 2024 Dec 30.
38. Navarro S, Le J, Tsui J, Barzi A, Stern MC, Pickering T, Farias AJ. Patient-Physician Communication Experience Modifies Racial/Ethnic Health Care Disparities Among Surveillance, Epidemiology, and End Results-Consumer Assessment of Healthcare Providers and Systems Participants With Colorectal Cancer and Multiple Chronic Conditions. *Med Care.* 2025 Mar 1;63(3):256-265. Epub 2024 Dec 27.
39. Guo H, Malone KE, Heckbert SR, Li CI. Statin use after cancer diagnosis and survival among patients with cancer. *Cancer Causes Control.* 2025 Apr;36(4):443-455. Epub 2024 Dec 25.
40. Mulder CV, Yang X, Jee YH, Scott CG, Gao C, Cao Y, Hurson AN, Eriksson M, Vachon CM, Hall P, Antoniou AC, Kraft P, Gierach GL, Garcia-Closas M, Choudhury PP. Investigating the added value of incorporating mammographic density to an integrated breast cancer risk model with questionnaire-based risk factors and polygenic risk score. *Res Sq.* 2024 Dec 19.
41. Earla JR, Kurian AW, Kponee-Shovein K, Mahendran M, Song Y, Hua Q, Hilts A, Sun Y, Hirshfield KM, Robson M, Mejia JA. Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis. *Adv Ther.* 2025 Feb;42(2):886-903. Epub 2024 Dec 16.
42. Maithel SK, Wang R, Harton J, Yopp A, Shah SA, Rocha FG, Hernandez S, Cheng S, Ogale S, Tan R. Prognostic Significance of Recurrence and Timing of Recurrence on Survival Among Patients with Early-Stage Hepatocellular Carcinoma in U.S. Clinical Practice. *Ann Surg Oncol.* 2025 Feb;32(2):1054-1062. Epub 2024 Dec 2.
43. Wan G, Wang Q, Li Y, Xu G. Development and validation of a nomogram for predicting survival in gastric signet ring cell carcinoma patients treated with radiotherapy. *Sci Rep.* 2024 Dec 2;14(1):29963.

44. Zhang-Petersen C, Sowden M, Chen J, Burns J, Sprague BL. Changes to the US Preventive Services Task Force Screening Guidelines and Incidence of Breast Cancer. *JAMA Netw Open*. 2024 Dec 2;7(12):e2452688.
45. Hendrick RE, Monticciolo DL. Surveillance, Epidemiology, and End Results Data Show Increasing Rates of Distant-Stage Breast Cancer at Presentation in U.S. Women. *Radiology*. 2024 Dec;313(3):e241397.
46. Haas CB, Shiels MS, Pfeiffer RM, D'Arcy M, Luo Q, Yu K, Austin AA, Cohen C, Miller P, **Morawski BM**, Pawlish K, Robinson WT, Engels EA. Cancers with epidemiologic signatures of viral oncogenicity among immunocompromised populations in the United States. 2024 Dec. *J Natl Cancer Inst*, 116(12), 1983-1991.
47. Lal T, Kim U, Boutros CS, Chakraborty NN, Doh SJ, Towe CW, Hoehn RS. Disruptions in Lung Cancer Detection During COVID-19. *Cancers (Basel)*. 2024 Nov 29;16. (23).
48. Hennocq Q, Pouillot W, Bertolus C, Foy JP. Difference in survival and prognosis between malignant tumors of odontogenic origin. *J Stomatol Oral Maxillofac Surg*. 2024 Nov 28;126(6):102179. Epub 2024 Nov 28.
49. Devarajan A, Seah C, Zhang JY, Vasan V, Feng R, Chapman EK, Shigematsu T, Bederson J, Shrivastava RK. A four-hit mechanism is sufficient for meningioma development. *J Neurooncol*. 2025 Feb;171(3):599-607. Epub 2024 Nov 25.
50. Li SS, Schuldt R, Zafar F, To TM, Yellow-Duke A, Levine A, Girvan A, Spence S, Mikhael J. Effects of Socioeconomic Status and Healthcare Resource Availability on Survival in Older (≥ 66 years) Non-Hispanic Black Patients Versus Non-Hispanic White Patients With Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2025 Apr;25(4):285-292.e1. Epub 2024 Nov 22.
51. Burus T, Patel MI, Christian WJ, Huang B, Lang Kuhs KA. Sex-based differences in histologic lung cancer incidence trends in the United States, 2005-2019. *Int J Cancer*. 2025 May 1;156(9):1716-1725. Epub 2024 Nov 21.
52. Lin Y, Wang SF, Liang HW, Liu Y, Huang W, Pan XB. Surgery alone versus neoadjuvant chemoradiotherapy followed by surgery in patients with stage T2N0M0 esophageal cancer. *Sci Rep*. 2024 Nov 21;14(1):28898.
53. Sheng Y, Sun Y. Statistical Inference for Counting Processes Under Shape Heterogeneity. *Stat Med*. 2024 Dec 30;43(30):5849-5861. Epub 2024 Nov 19.
54. Worku EB, Khalil M, Woldesenbet S, Pawlik TM. Variation in Cost Centers Following Gastrointestinal Cancer Surgery. *Ann Surg Oncol*. 2025 Mar;32(3):1565-1574. Epub 2024 Nov 19.
55. Ituarte BE, Taylor MA, Thomas SI, Sharma D, Samson K, Oudenhoven M, Harter N, Wei EX, Wysong A. Clinical presentations and decreasing incidence of melanoma in pediatric and adolescent and young adult patients: 76,108 cases from a nationally representative cohort. *J Am Acad Dermatol*. 2025 Mar;92(3):511-519. Epub 2024 Nov 17.
56. Huang Y, Huang H, Wei T, Zhang A, Zhang H, Zhang Z, Xu Y, Wang R, Wan N, Li X, Li J, Li Y, Li F. Disparities, Trends, and Predictions to 2040 in Gastrointestinal Cancer Incidence, Mortality in the United States. *Am J Gastroenterol*. 2024 Nov 12;120(6):1367-1380.
57. Chan K, Palis BE, Cotler JH, Janczewski LM, Weigel RJ, Bentrem DJ, Ko CY. Association of commission on cancer accreditation with receipt of guideline-concordant care and survival among patients with colon cancer. *World J Surg*. 2025 Jan;49(1):34-45. Epub 2024 Nov 7.
58. Kulshrestha A, Taioli E, Wolf A, Flores R, Tuminello S. Paradoxical Improvement in Malignant Pleural Mesothelioma Outcomes Following Delayed Treatment Initiation. *Cancers (Basel)*. 2024 Nov 7;16. (22).
59. Munir MM, Woldesenbet S, Khalil M, Mehdi Khan MM, Dillhoff M, Pawlik TM. Variation in lymph node assessment after pancreatic cancer resection: Patient, surgeon, pathologist, or hospital? *Am J Surg*. 2025 Mar;241:116067. Epub 2024 Nov 7.
60. Knisely A, Wu CF, Kanbergs A, Agusti N, Jorgensen KA, Melamed A, Giordano SH, Rauh-Hain JA, Nitecki Wilke R. Racial and sociodemographic disparities in the use of targeted

- therapies in advanced ovarian cancer patients with Medicare. *Int J Gynecol Cancer*. 2024 Nov 4;34(11):1661-1670.
61. Trentz C, Engelbart J, Semprini J, Kahl A, Anyimadu E, Buatti J, Casavant T, Charlton M, Canahuete G. Evaluating machine learning model bias and racial disparities in non-small cell lung cancer using SEER registry data. *Health Care Manag Sci*. 2024 Dec;27(4):631-649. Epub 2024 Nov 4.
 62. Chang SH, Cabrera R, Heo J, Park C, Guo J, Park H. Real-World Effectiveness of All-Oral Direct-Acting Antivirals in Patients With Hepatitis C Virus-Related HCC. *Clin Pharmacol Ther*. 2025 Apr;117(4):1030-1038. Epub 2024 Nov 3.
 63. Lee AW, Poynor V, Siddiqui S. Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020. *Gynecol Oncol*. 2024 Dec;191:292-298. Epub 2024 Nov 2.
 64. Ajani JA, Leung L, Kanters S, Singh P, Kurt M, Kim I, Pourrahmat MM, Friedman HS, Navaratnam P, Reardon G. Disease-free survival as surrogate for overall survival in real-world settings for esophageal cancer: an analysis of SEER-Medicare data. *ESMO Open*. 2024 Nov;9(11):103934. Epub 2024 Nov 6.
 65. Chatzipanagiotou OP, Woldesenbet S, Munir MM, Catalano G, Khalil M, Rashid Z, Altaf A, Pawlik TM. Impact of Contemporary Redlining on Healthcare Disparities Among Patients with Gastrointestinal Cancer: A Mediation Analysis. *Ann Surg Oncol*. 2025 Feb;32(2):1199-1209. Epub 2024 Nov 1.
 66. Washington Iii SL, Fakunle M, Wang L, Braun AE, Leapman M, Cowan JE, Cooperberg MR. County-level racial disparities in prostate cancer-specific mortality from 2005 to 2020. *JNCI Cancer Spectr*. 2024 Nov 1;8. (6).
 67. Bawany F, Pulavarty AN, Juarez MC, Criscito MC. Characterizing Merkel Cell Carcinoma in American Indians and Alaska Natives: A Retrospective Review of the Surveillance, Epidemiology, and End Results Database. *Dermatol Surg*. 2024 Dec 1;50(12S):S216-S218. Epub 2024 Oct 28.
 68. Lobo N, Duan Z, Sood A, Zhao H, Lindsdreg SV, Dyrskjot L, Giordano SH, Williams SB, Bree KK, Kamat AM. Sex Disparity in Non-muscle-invasive Bladder Cancer: Pitfalls of Large Population-based Data Sets and Lessons from an Integrated Analysis. *Eur Urol Oncol*. 2025 Jun;8(3):608-611. Epub 2024 Oct 23.
 69. Vadehra D, Sonti S, Siromoni B, Ramesh M, Mukhopadhyay D, Groman A, Iyer R, Mukherjee S. Demographic Characteristics and Survival in Young-Onset Colorectal Neuroendocrine Neoplasms. *Biomedicines*. 2024 Oct 21;12. (10).
 70. Adam N, Wieder R. AI Survival Prediction Modeling: The Importance of Considering Treatments and Changes in Health Status over Time. *Cancers (Basel)*. 2024 Oct 18;16. (20).
 71. Bressler SE, Evans AK. Pediatric non-nasopharyngeal head and neck squamous cell carcinoma: Analysis of the Surveillance, Epidemiology, and End Results (SEER) program with review of the literature. *Int J Pediatr Otorhinolaryngol*. 2024 Nov;186:112135. Epub 2024 Oct 15.
 72. Jannello LMI, Incesu RB, Morra S, Scheipner L, Baudo A, de Angelis M, Siech C, Tian Z, Goyal JA, Luzzago S, Mistretta FA, Ferro M, Saad F, Shariat SF, Chun FKH, Briganti A, Tilki D, Ahyai S, Carmignani L, Longo N, de Cobelli O, Musi G, Karakiewicz PI. The European Network for the Study of Adrenal Tumors Staging System (2015): A United States Validation. *J Clin Endocrinol Metab*. 2024 Oct 15;109(11):e2084-e2089.
 73. Mitchell AP, Persaud S, Mishra Meza A, Fuchs HE, De P, Tabatabai S, Chakraborty N, Dey P, Trivedi NU, Mailankody S, Blinder V, Green A, Epstein AS, Daly B, Roeker L, Bach PB, Gönen M. Quality of Treatment Selection for Medicare Beneficiaries With Cancer. *J Clin Oncol*. 2025 Feb 10;43(5):524-535. Epub 2024 Oct 11.

74. Alvarez GV, Liao KP, Wehner MR, Rogge MN. Melanoma risk in Turner syndrome: A case-control study in Surveillance, Epidemiology, and End Results-Medicare. *J Am Acad Dermatol*. 2025 Feb;92(2):321-323. Epub 2024 Oct 10.
75. Bell R, Weinberger DM, Venkatesh M, Fernandes-Taylor S, Francis DO, Davies L. Thyroid Cancer Incidence During 2020 to 2021 COVID-19 Variant Waves. *JAMA Otolaryngol Head Neck Surg*. 2024 Oct 10;150(11):969-77. Epub 2024 Oct 10.
76. Khan MMM, Woldesenbet S, Munir MM, Khalil M, Altaf A, Rashid Z, Pawlik TM. Variation in physician spending and its association with postoperative outcomes among patients undergoing surgery for gastrointestinal cancer. *J Gastrointest Surg*. 2024 Dec;28(12):2067-2074. Epub 2024 Oct 10.
77. Duchesneau ED, Reeder-Hayes K, Stürmer T, Kim DH, Edwards JK, Lund JL. Longitudinal trajectories of a claims-based frailty measure during adjuvant chemotherapy in women with stage I-III breast cancer. *Oncologist*. 2024 Oct 3;29(10):e1291-e1301.
78. Wang J, Pan Y, Chang CE, Daud A, Tao R, Hashibe M. Incident cardiovascular disease risk among older Asian, Native Hawaiian and Pacific Islander liver cancer survivors. *Cancer Epidemiol*. 2024 Dec;93:102680. Epub 2024 Oct 2.
79. Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL. Breast cancer statistics 2024. *CA Cancer J Clin*. 2024 Nov-Dec;74(6):477-495. Epub 2024 Oct 1.
80. Kim U, Rose J, Carroll BT, Hoehn RS, Chen E, Bordeaux JS, Koroukian SM. Recovery From COVID-19-Related Disruptions in Cancer Detection. *JAMA Netw Open*. 2024 Oct 1;7(10):e2439263.
81. Metwally E, Soppe SE, Lund JL, Hinton SP, Thompson CA. Impact of observability period on the classification of COPD diagnosis timing among Medicare beneficiaries with lung cancer. *PLOS Digit Health*. 2024 Oct 22;3(10):e0000633. doi: 10.1371/journal.pdig.0000633. eCollection 2024 Oct.
82. Minami CA, Dey T, Chen YJ, Freedman RA, Lorentzen EH, King TA, Mittendorf EA, Schonberg MA. Regional Variation in Deescalated Therapy in Older Adults With Early-Stage Breast Cancer. *JAMA Netw Open*. 2024 Oct 1;7(10):e2441152.
83. Uprety D, Seaton R, Hadid T, Mamdani H, Sukari A, Ruterbusch JJ, Schwartz AG. Racial and socioeconomic disparities in survival among patients with metastatic non-small cell lung cancer. *J Natl Cancer Inst*. 2024 Oct 1;116(10):1697-1704.
84. Braafladt S, Allison H, Chung J, Mariash CN, Bhattacharyya O, McDow AD, Haggstrom DA. Dose-dependent relationship between levothyroxine and health-related quality of life in survivors of differentiated thyroid cancer. *Surgery*. 2025 Mar;179:108799. Epub 2024 Sep 27.
85. Karim A, Troester A, Mott SL, Arsoniadis E, Jensen C, Hassan I, Kandagatla P, Goffredo P. A Population-Level Validation of the New 9th Edition of the American Joint Commission on Cancer Staging System for Anal Squamous Cell Carcinoma. *J Surg Oncol*. 2025 Mar;131(3):481-488. Epub 2024 Sep 27.
86. Yu C, Shi Z, Zhou G, Chang X. Revisiting the survival paradox between stage IIB/C and IIIA colon cancer. *Sci Rep*. 2024 Sep 27;14(1):22133.
87. Li M, Zeng Q, Chen Y, Zhao J. The role of wedge resection and lymph node examination in stage IA lung carcinoid tumors. *J Thorac Dis*. 2024 Sep 30;16(9):5969-5980. Epub 2024 Sep 26.
88. Bleyer A, Tai E, Siegel S, Roth M, DeAngelo DJ, Stock W. Abatement of the Survival Cliff in Older Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in the United States. *J Adolesc Young Adult Oncol*. 2025 Feb;14(1):33-42. Epub 2024 Sep 25.
89. Yuan C, Zheng H. Brain metastases in newly diagnosed lung cancer: epidemiology and conditional survival. *Transl Cancer Res*. 2024 Oct 31;13(10):5417-5428. Epub 2024 Sep 25.

90. Siech C, de Angelis M, Di Bello F, Rodriguez Peñaranda N, Goyal JA, Tian Z, Saad F, Shariat SF, Puliatti S, Longo N, Briganti A, Banek S, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival. *Ann Surg Oncol*. 2024 Dec;31(13):8993-9001. Epub 2024 Sep 23.
91. Gohil S, Chen H, Lewis WE, Trivedi M, Aparasu RR, Johnson ML. Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study. *J Geriatr Oncol*. 2024 Nov;15(8):102071. Epub 2024 Sep 22.
92. Hemminki K, Zitricky F, Försti A, Tapaninen T, Hemminki A, Juliusson G, Niemann CU. Complex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden. *Cancers (Basel)*. 2024 Sep 22;16. (18).
93. Tsilimigras DI, Woldesenbet S, Chatzipanagiotou OP, Iyer S, Pawlik TM. Long-term lorazepam use may be associated with worse long-term outcomes among patients with pancreatic adenocarcinoma. *Surgery*. 2025 Mar;179:108794. Epub 2024 Sep 20.
94. Gleason EG, Saris DH, Tubridy EA, Brensinger CM, Ko EM. Racial disparities in receipt of radiation and brachytherapy in cervical cancer patients: Do they exist in a SEER-Medicare population? *Gynecol Oncol Rep*. 2024 Sep 19;55:101505. doi: 10.1016/j.gore.2024.101505. eCollection 2024 Oct.
95. Kohn JF, Boatman S, Wang Q, Marmor S, Hassan I, Madoff RD, Gaertner WB, Goffredo P. Splenic flexure adenocarcinoma: A national cohort analysis of extent of surgical resection and outcomes. *Colorectal Dis*. 2024 Nov;26(11):1883-1891. Epub 2024 Sep 18.
96. Bozigar M, Konstantinoudis G, Zilli Vieira CL, Li L, Alwadi Y, Jones RR, Koutrakis P. Domestic radon exposure and childhood cancer risk by site and sex in 727 counties in the United States, 2001-2018. *Sci Total Environ*. 2024 Dec 1;954:176288. Epub 2024 Sep 14.
97. Zhang L, Muscat JE, Chinchilli VM, Behura CG. Trends in Cancer Incidence and Mortality in US Adolescents and Young Adults, 2016-2021. *Cancers (Basel)*. 2024 Sep 14;16. (18).
98. Kang JW, Noh JK, Lee MK, Lee YS, Lee YC, Lee JW, Kong M, Ko SG, Eun YG. Poor Survival of Patients With Very Small But Locally Advanced (T4) Oropharyngeal Cancer. *Ear Nose Throat J*. 2024 Sep 11: 1455613241271686. Epub 2024 Sep 11.
99. Bishop B, Hockenberry H, Sperber J, Owolo E, Baeta C, Price M, Neff C, Kruchko C, Barnholtz-Sloan JS, Charles AJ, Sciubba C, Ostrom QT, Johnson E, Goodwin CR. The intersection of race, ethnicity, and urbanicity on treatment paradigms and clinical outcomes for non-malignant primary tumors of the spine. *Cancer Epidemiol*. 2024 Dec;93:102657. Epub 2024 Sep 6.
100. Cavazzani A, Angelini C, Gregori D, Cardone L. Cancer incidence (2000-2020) among individuals under 35: an emerging sex disparity in oncology. *BMC Med*. 2024 Sep 4;22(1):363.
101. Suarez-Almazor ME, Ruiz JI, Lei X, Wu CF, Zhao H, Rajan SS, Giordano SH. Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer. *Clin Rheumatol*. 2024 Nov;43(11):3301-3312. Epub 2024 Sep 4.
102. Aslani A, Morsali S, Mousavi SE, Choupani S, Yekta Z, Nejadghaderi SA. Adult Hodgkin lymphoma incidence trends in the United States from 2000 to 2020. *Sci Rep*. 2024 Sep 3;14(1):20500.
103. Burus T, Lei F, Huang B, Christian WJ, Hull PC, Ellis AR, Slavova S, Tucker TC, Lang Kuhs KA. COVID-19 and Rates of Cancer Diagnosis in the US. *JAMA Netw Open*. 2024 Sep 3;7(9):e2432288.
104. Hahn T, Herr MM, Brazauskas R, Patel J, Ailawadhi S, Saber W, Khera N. Use of Hematopoietic Cell Transplant for Hematologic Cancers by Race, Ethnicity, and Age. *JAMA Netw Open*. 2024 Sep 3;7(9):e2433145.

105. Fish K, Gao D, Raji M, Balducci L, Kuo YF. Trends in the use of granulocyte colony stimulating factors for older patients with cancer, 2010 to 2019. *J Geriatr Oncol*. 2024 Nov;15(8):102049. Epub 2024 Sep 2.
106. Garg A, Damgacioglu H, Sigel K, Nyitray AG, Clifford GM, Curran T, Lazenby G, Meissner EG, Sterba K, Sonawane K, Deshmukh AA. Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035. *J Natl Cancer Inst*. 2024 Sep 1;116(9):1508-1512.
107. Gore JL, Wright P, Shih V, Chang NN, Noshad S, Rey GG, Wang S, Narayanan S. Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data. *JCO Clin Cancer Inform*. 2024 Sep;8:e2400073.
108. Liu B, Yu M, Byrne J, Cronin KA, Feuer EJ. The COVID-19 pandemic and associated declines in cancer incidence by race/ethnicity and census-tract level SES, rurality, and persistent poverty status. *Cancer Med*. 2024 Sep;13(17):e70220.
109. Dmukauskas M, Cioffi G, Waite KA, Mammoser AG, Sloan AE, Ma PC, Barnholtz-Sloan JS. Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age. *Cancers (Basel)*. 2024 Aug 28;16. (17).
110. Wang Y, Alsaraf Y, Bandaru SS, Lyons S, Reap L, Ngo T, Yu Z, Yu Q. Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma. *J Gastrointest Oncol*. 2024 Aug 31;15(4):1777-1788. Epub 2024 Aug 28.
111. Tan JY, Shen SH. Nomogram predicting the cardiovascular disease mortality for older patients with colorectal cancer: A real-world population-based study. *World J Cardiol*. 2024 Aug 26;16(8):458-468.
112. Cheng Z, Jia Z, Li X, Chen L, Cai Y. Unmasking the silent killer: The hidden aggressiveness of signet-ring cell carcinoma in gallbladder cancer. *Biosci Trends*. 2024 Sep 16;18(4):379-387. Epub 2024 Aug 25.
113. Chen N, Hu CR, Iyer HS, James P, Dickerman BA, Mucci LA, Nethery RC. Neighborhood greenness and long-term physical and psychosocial quality of life among prostate cancer survivors in the Health Professionals Follow-up Study. *Environ Res*. 2024 Dec 1;262(Pt 1):119847. Epub 2024 Aug 24.
114. Bakaloudi DR, Koehne EL, Diamantopoulos LN, Holt SK, Sekar RR, Ghali F, Vakar-Lopez F, Nyame YA, Psutka SP, Gore JL, de la Calle CM, Lin DW, Schade GR, Liao JJ, Hsieh AC, Yezefski T, Hawley JE, Yu EY, Montgomery RB, Grivas P, Wright JL. Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study. *Clin Genitourin Cancer*. 2024 Dec;22(6):102208. Epub 2024 Aug 22.
115. Brick R, Williams CP, Deng L, Mollica MA, Stout N, Gorzelitz J. Associations Between Rehabilitation Utilization and Out-of-Pocket Costs Among Older Adults With Breast Cancer in the United States. *Arch Phys Med Rehabil*. 2024 Dec;105(12):2301-2308. Epub 2024 Aug 21.
116. Katayama ES, Thammachack R, Woldesenbet S, Khalil M, Munir MM, Tsilimigras D, Pawlik TM. The Association of Established Primary Care with Postoperative Outcomes Among Medicare Patients with Digestive Tract Cancer. *Ann Surg Oncol*. 2024 Nov;31(12):8170-8178. Epub 2024 Aug 19.
117. Mukand NH, Chirikova E, Lichtensztajn D, Negoita S, Aboushwareb T, Bennett J, Brooks JD, Leppert JT, Chung BI, Li C, Schwartz SM, Gershman ST, Insaf T, **Morawski BM**, Stroup A, Wu XC, Doherty JA, Petkov VI, Zambon JP, Gomez SL, Cheng I. Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake. *Cancer*. 2024 Dec 15;130(24):4298-4305. Epub 2024 Aug 19.

118. Yang T, Zheng H, Chen S, Gong M, Liu Y, Zhou W, Ye J, Pan X, Cui X. Impact of tumor multiplicity on the prognosis of patients with primary renal cell carcinoma: a SEER database analysis. *Clin Exp Med*. 2024 Aug 17;24(1):194.
119. Mali B, Mali A, Mali A, Abdulrazzak M, Jobran AWM. The epidemiological and clinical characteristics of Langerhans cell sarcoma in the United States: A population study based on SEER data from 2000 to 2019. *Medicine (Baltimore)*. 2024 Aug 16;103(33):e39315.
120. Shen N, Ramanathan S, Horns JJ, Hyngstrom JR, Bowles TL, Grossman D, Asare EA. The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER Medicare data (2010-2018). *Am J Surg*. 2024 Nov;237:115896. Epub 2024 Aug 14.
121. Qian J, Truong B. Initiation of Oral Endocrine Therapy and Survival Benefit Among Women with Early-Stage Breast Cancer. *J Womens Health (Larchmt)*. 2024 Nov;33(11):1509-1517. Epub 2024 Aug 12.
122. Stencil MG, Wu S, Danielle SR, Yabes JG, Davies BJ, Sabik LM, Jacobs BL. Stereotactic Body Radiation Adoption Impacts Prostate Cancer Treatment Patterns. *Urology*. 2024 Dec;194:111-119. Epub 2024 Aug 10.
123. Keeney T, Miller A, Gilissen J, Coombs LA, Ritchie CS, McCarthy EP. Identification of older adults with Alzheimer's and related dementias among patients newly diagnosed with cancer: A comparison of methodological approaches. *J Geriatr Oncol*. 2024 Sep;15(7):101842. Epub 2024 Aug 9.
124. Gorzelitz JS, Brick R, Deng L, Mollica M, Stout N, Stoller S, Williams CP. Sociodemographic and clinical characteristics associated with rehabilitation services utilization in older women with early-stage breast cancer from SEER-Medicare 2009-2018. *J Cancer Surviv*. 2024 Aug 8. Epub 2024 Aug 8.
125. Ruiz JI, Lei X, Chi-Fang W, Giordano SH, Zhao H, Rajan SS, Lin H, Suarez-Almazor ME. Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors. *Breast Cancer*. 2024 Nov;31(6):1059-1070. Epub 2024 Aug 8.
126. Ma J, Ma X, Xing J, Song R, Zhang Y, Liu M, Guo S, Zhang Q, Wu J. Clinical and pathological characteristics of and predictive model for colorectal neuroendocrine tumors. *Heliyon*. 2024 Aug 2;10(15):e35720. doi: 10.1016/j.heliyon.2024.e35720. eCollection 2024 Aug 15.
127. Bhattacharya M, Cronin KA, Farrigan TL, Kennedy AE, Yu M, Srinivasan S. Description of census-tract-level social determinants of health in cancer surveillance data. *J Natl Cancer Inst Monogr*. 2024 Aug 1;2024(65):152-161.
128. Gupta A, Akinyemiju T. Early-onset cancer incidence in the United States by race/ethnicity between 2011 and 2020. *Cancer Epidemiol*. 2024 Oct;92:102632. Epub 2024 Aug 1.
129. Hong YD, Enewold L, Sharon E, Warner JL, Davidoff AJ, Zeruto C, Mariotto AB. Evolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma. *Cancer Med*. 2024 Aug;13(16):e70131.
130. Howlader N, Lund JL, Enewold L, Stevens J, McNeel T, Rivera D, Mariotto A, Cronin KA. Real-world lessons: combining cancer registry and retail pharmacy data for oral cancer drugs. *J Natl Cancer Inst Monogr*. 2024 Aug 1;2024(65):162-167.
131. Jain S, Long JB, Rao V, Law AC, Walkey AJ, Prsic E, Lindenauer PK, Krumholz HM, Gross CP. Trends in use of intensive care during hospitalizations at the end-of-life among older adults with advanced cancer. *J Am Geriatr Soc*. 2024 Dec;72(12):3840-3848. Epub 2024 Aug 1.
132. Liu X, Alipour GH, Shao C, Burcu M, Bortnichak E, Vo T, Yu CL. The Comparison of Newly Diagnosed Invasive Breast Patient Cohorts in Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative (GENIE-BPC) and Other Real-World Databases. *Pharmacoepidemiol Drug Saf*. 2024 Aug;33(8):e5851.

133. Melkonian SC, Jim MA, Haverkamp D, Lee M, Janitz AE, Campbell JE. Kidney Cancer Incidence among Non-Hispanic American Indian and Alaska Native Populations in the United States, 1999 to 2020. *Cancer Epidemiol Biomarkers Prev.* 2024 Aug 1;33(8):1065-1072.
134. Deapen D, Clerkin C, Howe W, Green D, **Johnson CJ**, Kohler BA, Landgren AM, Preda A, Elena J, Penberthy L. Virtual Pooled Registry-Cancer Linkage System: an improved method for ascertaining cancer diagnoses. *J Natl Cancer Inst Monogr.* 2024 Aug 1;2024(65):191-197. doi: 10.1093/jncimonographs/lgae005. PMID: 39102879; PMCID: PMC11300027.
135. Petkov VI, Byun JS, Ward KC, Schussler NC, Archer NP, Bentler S, Doherty JA, Durbin EB, Gershman ST, Cheng I, Insaf T, Gonsalves L, Hernandez BY, Koch L, Liu L, Monnereau A, **Morawski BM**, Schwartz SM, Stroup A, Wiggins C, Wu XC, Bonds S, Negoita S, Penberthy L. Reporting tumor genomic test results to SEER registries via linkages. *J Natl Cancer Inst Monogr.* 2024 Aug 1;2024(65):168-179.
136. Pollack CE, Garrison V, Johnson T, Blackford AL, Banks B, Howe W, Yabroff KR, Enewold L. Housing assistance among patients with cancer: SEER-Medicare US Department of Housing and Urban Development data linkage. *J Natl Cancer Inst.* 2024 Aug 1;116(8):1270-1279.
137. Richardson DR, Zhou X, Reeder-Hayes K, Jensen CE, Islam J, Loh KP, Gupta A, Basch E, Bennett AV, Bridges JFP, Wheeler SB, Wood WA, Baggett CD, Lund JL. Home Time Among Older Adults With Acute Myeloid Leukemia Following Chemotherapy. *JAMA Oncol.* 2024 Aug 1;10(8):1038-1046.
138. Semprini J, Gadag K, Williams G, Muldrow A, Zahnd WE. Rural-Urban Cancer Incidence and Trends in the United States, 2000 to 2019. *Cancer Epidemiol Biomarkers Prev.* 2024 Aug 1;33(8):1012-1022.
139. Wijayabahu AT, McGee-Avila JK, Shiels MS, Harsono AAH, Arend RC, Clarke MA. Five-Year Relative Survival Rates of Women Diagnosed with Uterine Cancer by County-Level Socioeconomic Status Overall and across Histology and Race/Ethnicity. *Cancers (Basel).* 2024 Aug 1;16. (15).
140. Qi W, Wang Z, Zhang M. Segmentectomy and wedge resection are equivalent for the treatment of early-stage pulmonary carcinoid tumors: A retrospective cohort study. *Sci Rep.* 2024 Jul 31;14(1):17742.
141. George LS, Duberstein PR, Keating NL, Bates B, Bhagianadh D, Lin H, Saraiya B, Goel S, Akincigil A. Estimating oncologist variability in prescribing systemic cancer therapies to patients in the last 30 days of life. *Cancer.* 2024 Nov 1;130(21):3757-3767. Epub 2024 Jul 30.
142. Lu T, Wang H, Liu Y, Qin X, Teng Y, Wang Y. Demographic and clinical data of patients with spinal epidural angioliipomas. *Sci Rep.* 2024 Jul 29;14(1):17473.
143. Salz T, Meza AM, Bradshaw PT, Jinna S, Moryl N, Kriplani A, R Tringale K, Flory J, Korenstein D, Lipitz-Snyderman A. Role of primary care in opioid prescribing for older head and neck cancer survivors. *Cancer.* 2024 Nov 15;130(22):3913-3925. Epub 2024 Jul 27.
144. Qin JJ, Zhu XX, Chen X, Sang W, Jin YL. Comparison of Cox regression and generalized Cox regression models to machine learning in predicting survival of children with diffuse large B-cell lymphoma. *Transl Cancer Res.* 2024 Jul 31;13(7):3370-3381. Epub 2024 Jul 26.
145. Mahashabde RV, Bhatti SA, Martin BC, Painter JT, Rodriguez A, Ying J, Li C. Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases. *Transl Lung Cancer Res.* 2024 Jul 30;13(7):1620-1634. Epub 2024 Jul 25.
146. Metwally EM, Lund JL, Drummond MB, Peacock Hinton S, Poole C, Thompson CA. COPD With Lung Cancer Among Older United States Adults: Prevalence, Diagnostic

- Timeliness, and Association With Earlier Stage Tumors. *Chronic Obstr Pulm Dis*. 2024 Jul 25;11(4):382-385.
147. Ji YT, Liu SW, Zhang YM, Duan HY, Liu XM, Feng ZW, Li JJ, Lyu ZY, Huang YB. [Comparison of the latest cancer statistics, cancer epidemic trends and determinants between China and the United States]. *Zhonghua Zhong Liu Za Zhi*. 2024 Jul 23;46(7):646-656.
 148. Meagher M, Morgan K, Deshler L, Riviere P, Dolendo I, Rose B, Jamieson C, Morris S, Nik-Ahd F, Freedland S, Anger J, Salmasi A. Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival. *Cancer*. 2024 Nov 15;130(22):3863-3869. Epub 2024 Jul 21.
 149. Sundaresan VM, Wang R, Long JB, Sprenkle PC, Seibert TM, Loeb S, Cooperberg MR, Catalona WJ, Ma X, Gross CP, Leapman MS. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. *Urol Pract*. 2024 Nov;11(6):965-973. Epub 2024 Jul 16.
 150. Liang M, Huang J, Liu C, Chen M. Predictive Modeling of Long-Term Prognosis After Resection in Typical Pulmonary Carcinoid: A Machine Learning Perspective. *Cancer Invest*. 2024 Aug;42(7):544-558. Epub 2024 Jul 15.
 151. Roberts B, Lewis R, Smith S, Miller E, Pierce J. Historical cosmetic talc consumption and incidence of mesothelioma in the United States. *Int J Environ Health Res*. 2025 Apr;35(4):972-980. Epub 2024 Jul 14.
 152. Preston MA, Ebrahimi R, Hong A, Bobbili P, Desai R, Duh MS, Gandhi R, Hanson S, Dufour R, Morgans AK. Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer. *Urol Oncol*. 2024 Dec;42(12):447.e1-447.e9. Epub 2024 Jul 12.
 153. Wu SN, Qin DY, Zhu L, Guo SJ, Li X, Huang CH, Hu J, Liu Z. Uveal melanoma distant metastasis prediction system: A retrospective observational study based on machine learning. *Cancer Sci*. 2024 Sep;115(9):3107-3126. Epub 2024 Jul 11.
 154. Mousavi SE, Ilaghi M, Aslani A, Najafi M, Yekta Z, Nejadghaderi SA. Laryngeal cancer incidence trends in the United States over 2000-2020: a population-based analysis. *Arch Public Health*. 2024 Jul 10;82(1):106.
 155. Siech C, de Angelis M, Jannello LMI, Di Bello F, Rodriguez Peñaranda N, Goyal JA, Tian Z, Saad F, Shariat SF, Puliatti S, Longo N, de Cobelli O, Briganti A, Hoeh B, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality. *Prostate Cancer Prostatic Dis*. 2025 Sep;28(3):748-754. Epub 2024 Jul 10.
 156. Cogua LM, Tupper CJ, Silberstein PT, Coan KE. Intermediate-sized follicular thyroid cancer surgical trends before and after the 2015 American thyroid association guideline changes. *Am J Surg*. 2024 Dec;238:115830. Epub 2024 Jul 9.
 157. Latoni DI, Geller AC, Semenov YR, Ji Z, Tsao H. Geotemporal Analysis of Melanoma Incidence and Mortality Identifies Distinct Clusters of Trends within the United States Between 2001 and 2019. *J Invest Dermatol*. 2025 Feb;145(2):393-399.e1. Epub 2024 Jul 7.
 158. Morra S, Cano Garcia C, Piccinelli ML, Tappero S, Barletta F, Incesu RB, Scheipner L, Baudo A, Tian Z, de Angelis M, Mirone V, Califano G, Celentano G, Saad F, Shariat SF, Chun FKH, de Cobelli O, Musi G, Terrone C, Briganti A, Tilki D, Ahyai S, Carmignani L, Longo N, Karakiewicz PI. Survival of stage III non-seminoma testis cancer patients versus simulated controls, according to race/ethnicity. *Int J Urol*. 2024 Oct;31(10):1137-1143. Epub 2024 Jul 5.
 159. Davies GA, Orav JE, Brantley KD. Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study. *Curr Oncol*. 2024 Jul 4;31(7):3885-3894.

160. Semprini J. Explicit inference: A meta-replication of SEER cancer registry research evaluating the Affordable Care Act's Medicaid expansion. *J Eval Clin Pract.* 2024 Dec;30(8):1531-1538. Epub 2024 Jul 3.
161. Abboud Y, Singh L, Fraser M, Pan CW, Abboud I, Mohamed IH, Kim D, Alsakarneh S, Jaber F, Richter B, Al-Khazraji A, Hajifathalian K, Vossough-Teehan S. Racial and ethnic disparities in gallbladder cancer: A two-decade analysis of incidence and mortality rates in the US. *Cancer Med.* 2024 Jul;13(13):e7457.
162. Chen N, McGrath CB, Stopsack KH, Morgans AK, Nethery RC, Dickerman BA, Mucci LA. Social integration and long-term physical and psychosocial quality of life among prostate cancer survivors in the Health Professionals Follow-up Study. *J Cancer Surviv.* 2024 Jul 1. Epub 2024 Jul 1.
163. Koric A, Chang CE, Lee YA, Wei M, Lee CJ, Tao R, Wang J, Tay D, Hashibe M. Incident diabetes among older Asian, Native Hawaiian, and Pacific Islander women with breast cancer. *JNCI Cancer Spectr.* 2024 Jul 1;8. (4).
164. Anderson LJ, Girguis M, Kim E, Shewale J, Braunlin M, Werther W, Hidalgo-Lopez JE, Zaman F, Kim C. A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden. *Leuk Lymphoma.* 2024 Oct;65(10):1482-1492. Epub 2024 Jun 27.
165. Zhou YJ, Tan ZE, Zhuang WD, Xu XH. Analysis of cancer-specific survival in patients with metastatic colorectal cancer: A evidence-based medicine study. *World J Gastrointest Surg.* 2024 Jun 27;16(6):1791-1802.
166. Leng J, Qiu H, Huang Q, Zhang J, Zhou H. Recommendations for broadening eligibility criteria in esophagus cancer clinical trials: the mortality disparity of esophagus cancer as a first or second primary malignancy. *J Thorac Dis.* 2024 Jun 30;16(6):3882-3896. Epub 2024 Jun 24.
167. Wijayabahu AT, Shiels MS, Arend RC, Clarke MA. Uterine cancer incidence trends and 5-year relative survival by race/ethnicity and histology among women under 50 years. *Am J Obstet Gynecol.* 2024 Nov;231(5):526.e1-526.e22. Epub 2024 Jun 24.
168. Charalel RA, Mushlin AI, Zheng X, Mao J, Carlos RC, Brown RS Jr, Ibrahim S, Fortune BE, Talenfeld AD, Madoff DC, Johnson MS, Sedrakyan A. Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison. *AJR Am J Roentgenol.* 2024 Aug;223(2):e2431272. Epub 2024 Jun 20.
169. C Patel D, He H, Z Liou D, J Speicher P, F Berry M. Population-Based Analysis of Local Therapies for Large (>7 cm) Non-Small Cell Lung Cancer Tumors. *Thorac Res Pract.* 2024 Jun 17;25(4):141-148.
170. Yu X, Pan M, Ye J, Hathaway CA, Tworoger SS, Lea J, Li B. Quantifiable TCR repertoire changes in prediagnostic blood specimens among patients with high-grade ovarian cancer. *Cell Rep Med.* 2024 Jul 16;5(7):101612. Epub 2024 Jun 14.
171. Booth A, Brinton D, Donahue C, Westfal M, George V, Maxwell PJ, Simpson K, Mahvi D, Curran T. Extended Pharmacologic Prophylaxis for Venous Thromboembolism After Colon Cancer Surgery Is Associated With Improved Long-term Survival: A Natural Experiment in the Chemotherapeutic Benefit of Heparin Derivatives. *Ann Surg.* 2024 Oct 1;280(4):595-603. Epub 2024 Jun 11.
172. Byun JY, Aiyeolemi A, Qdaisat A, Park C. Association between epidermal growth factor receptor-tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non-small cell lung cancer. *Cancer.* 2024 Oct 15;130(20):3412-3425. Epub 2024 Jun 7.
173. Goyal RK, Candrilli SD, Abughosh S, Chen H, Holmes HM, Johnson ML. Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer. *Cancers (Basel).* 2024 Jun 7;16. (12).

174. Truong B, Hornsby L, Fox B, Chou C, Zheng J, Qian J. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from SEER-Medicare Database. *Cardiovasc Drugs Ther.* 2025 Aug;39(4):823-835. Epub 2024 Jun 7.
175. Homer AS, Kasthuri VS, Homer BJ, Jain R, Gall EK, Noonan KY. The Association Between Medicaid Expansion and Disparities in Vestibular Schwannoma Incidence. *Laryngoscope.* 2024 Oct;134(10):4383-4388. Epub 2024 Jun 4.
176. Krok-Schoen JL, Nikahd M, Hyer M, Felix AS, Nolan TS, Ridgway-Limle EA, Xu M, Quick AM, Paoletta C, Horn M, Arthur EK. Social determinants of health and depressive symptoms before and after cancer diagnosis. *J Women Aging.* 2024 Sep-Oct;36(5):398-409. Epub 2024 Jun 3.
177. Liu T, Gao Y, Li S, Xu S. Exploration and prognostic analysis of two types of high-risk ovarian cancers: clear cell vs. serous carcinoma: a population-based study. *J Ovarian Res.* 2024 Jun 1;17(1):119.
178. Mousavi SE, Ghasemi H, Najafi M, Yekta Z, Nejadghaderi SA. Incidence Trends of Vulvar Cancer in the United States: A 20-Year Population-Based Study. *Cancer Rep (Hoboken).* 2024 Jun;7(6):e2120.
179. Atre SY, Soulos PR, Kuderer NM, Gross CP, Baum LVM, Dinan MA, Lustberg MB. Characterization of time toxicity in older patients with metastatic breast cancer. *Breast Cancer Res Treat.* 2024 Oct;207(3):541-550. Epub 2024 May 31.
180. Adam N, Wieder R. Temporal Association Rule Mining: Race-Based Patterns of Treatment-Adverse Events in Breast Cancer Patients Using SEER-Medicare Dataset. *Biomedicines.* 2024 May 29;12. (6).
181. Yang Z, Jiang H, He D, Zhang S, Huang L, Gao P, Huang H, Cao J, Zhan Z. Developing a nomogram based on SEER database for predicting prognosis in choroid plexus tumors. *Sci Rep.* 2024 May 28;14(1):12219.
182. Abboud Y, Pirquet C, Timmons K, Abboud I, Awadallah M, Al-Khazraji A, Hajifathalian K. The National Landscapes of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: Stable Trends in Black Populations and Late-Stage Tumors. *Cancers (Basel).* 2024 May 27;16. (11).
183. Westerlinck P, Coucke P, Albert A. Development of a cancer risk model and mobile health application to inform the public about cancer risks and risk factors. *Int J Med Inform.* 2024 Sep;189:105503. Epub 2024 May 27.
184. Zillioux J, Camacho FT, Anderson RT, You W, Rapp DE. Prevalence of Cognitive and Manual Dexterity Disorders Among Men Following Artificial Urinary Sphincter Placement. *J Urol.* 2024 Sep;212(3):441-450. Epub 2024 May 24.
185. Song BB, Anderson ZS, Masjedi AD, Lee MW, Mandelbaum RS, Klar M, Roman LD, Wright JD, Matsuo K. Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer. *Obstet Gynecol.* 2024 Jul 1;144(1):68-78. Epub 2024 May 23.
186. Morra S, Incesu RB, Scheipner L, Baudo A, Jannello LMI, Siech C, de Angelis M, Tian Z, Creta M, Califano G, Collà Ruvolo C, Saad F, Shariat SF, Chun FKH, de Cobelli O, Musi G, Briganti A, Tilki D, Ahyai S, Carmignani L, Longo N, Karakiewicz PI. Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients. *World J Urol.* 2024 May 22;42(1):343.
187. Wang J, Im Y, Wang R, Ma S. Partial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis. *Life (Basel).* 2024 May 22;14. (6).
188. Incesu RB, Morra S, Scheipner L, Baudo A, Cano Garcia C, Barletta F, Assad A, Tian Z, Saad F, Shariat SF, Briganti A, Chun FKH, Carmignani L, Ahyai S, Longo N, Tilki D, Graefen M, Karakiewicz PI. Sarcomatoid Dedifferentiation as a Predictor of Cancer-Specific Mortality

- in Surgically Treated Localized Renal Cell Carcinoma. *Ann Surg Oncol*. 2024 Aug;31(8):5457-5464. Epub 2024 May 21.
189. Mohr C, Liao K, Hinkston CL, Wehner MR, Li M. Factors Associated with Adoption of Immune Checkpoint Inhibitor Treatment for Advanced Melanoma: A SEER-Medicare Cohort Study. *JID Innov*. 2024 May 21;4(4):100289. doi: 10.1016/j.xjidi.2024.100289. eCollection 2024 Jul.
 190. Khalil M, Woldesenbet S, Munir MM, Khan MMM, Rashid Z, Altaf A, Katayama E, Endo Y, Dillhoff M, Tsai S, Pawlik TM. Long-term Health Outcomes of New Persistent Opioid Use After Gastrointestinal Cancer Surgery. *Ann Surg Oncol*. 2024 Aug;31(8):5283-5292. Epub 2024 May 18.
 191. Imperiale TF, Myers LJ, Barker BC, Stump TE, Daggy JK. Colon Age: A Metric for Whether and How to Screen Male Veterans for Early-Onset Colorectal Cancer. *Cancer Prev Res (Phila)*. 2024 Aug 1;17(8):377-84. Epub 2024 May 17.
 192. Mousavi SE, Najafi M, Aslani A, Fazlollahi A, Yekta Z, Sadri M, Nejadghaderi SA. A population-based study on incidence trends of kidney and renal pelvis cancers in the United States over 2000-2020. *Sci Rep*. 2024 May 17;14(1):11294.
 193. Neff C, Price M, Cioffi G, Liu Z, Walsh R, Barnholtz-Sloan JS, Walsh KM, Salama AKS, Anders CK, Fecci PE, Ostrom QT. Atopy improves survival and decreases risk of brain metastasis in cutaneous melanoma. *medRxiv*. 2024 May 15.
 194. DuBois TD, Henry KA, Siegel SD, Lynch SM. Geographic Disparities in Cancer Incidence in the US Population Aged 20 to 49 Years, 2016-2020. *Prev Chronic Dis*. 2024 May 9;21:E32.
 195. Yang SS, Yang XG, Yang XH, Hu XH. Prognostic factors and novel prediction models for overall survival of patients with submandibular gland cancer: A population-based retrospective cohort study. *Heliyon*. 2024 May 9;10(10):e30860. doi: 10.1016/j.heliyon.2024.e30860. eCollection 2024 May 30.
 196. Incesu RB, Morra S, Scheipner L, Barletta F, Baudo A, Garcia CC, Tappero S, Piccinelli ML, Tian Z, Saad F, Shariat SF, de Cobelli O, Terrone C, Chun FKH, Carmignani L, Briganti A, Ahyai S, Longo N, Tilki D, Graefen M, Karakiewicz PI. A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer. *Jpn J Clin Oncol*. 2024 May 7;54(5):592-598.
 197. Guo H, Malone KE, Heckbert SR, Li CI. Statin use and risks of breast cancer recurrence and mortality. *Cancer*. 2024 Sep 15;130(18):3106-3114. Epub 2024 May 6.
 198. Nikita N, Gandhi K, Keith SW, Sharma S, Kelly WK, Lu-Yao G. The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based study. *J Geriatr Oncol*. 2024 Jun;15(5):101773. Epub 2024 May 3.
 199. Uhlig J, Uhlig A, Deshpande H, Ströbel P, Trojan L, Lotz J, Hurwitz M, Hafez O, Humphrey P, Grünwald V, Kim HS. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. *Sci Rep*. 2024 May 2;14(1):10038.
 200. Abboud Y, Fraser M, Qureshi I, Srivastava S, Abboud I, Richter B, Jaber F, Alsakarneh S, Al-Khazraji A, Hajifathalian K. Geographical Variations in Early Onset Colorectal Cancer in the United States between 2001 and 2020. *Cancers (Basel)*. 2024 May 1;16. (9).
 201. Burus T, Damgacioglu H, Huang B, Christian WJ, Hull PC, Ellis AR, Arnold SM, Deshmukh AA, Lang Kuhs KA. Trends in Oral Tongue Cancer Incidence in the US. *JAMA Otolaryngol Head Neck Surg*. 2024 May 1;150(5):436-443.
 202. Qin L, Li H, Zheng D, Lin S, Ren X. Glioblastoma patients' survival and its relevant risk factors during the pre-COVID-19 and post-COVID-19 pandemic: real-world cohort study in the USA and China. *Int J Surg*. 2024 May 1;110(5):2939-2949.
 203. Sarabu N, Dong W, Koroukian SM. Disparities in treatment patterns and mortality in prostate cancer: Interaction between Black race and end-stage kidney disease. *Cancer Med*. 2024 May;13(10):e7027.

204. Hardell KNL, Schonfeld SJ, Ramin C, Vo JB, Morton LM. Association between diabetes and subsequent malignancy risk among older breast cancer survivors. *JNCI Cancer Spectr*. 2024 Apr 30;8. (3).
205. Thompson CA, Sheridan P, Metwally E, Peacock Hinton S, Mullins MA, Dillon EC, Thompson M, Pettit N, Kurian AW, Pruitt SL, Lyratzopoulos G. Emergency department involvement in the diagnosis of cancer among older adults: a SEER-Medicare study. *JNCI Cancer Spectr*. 2024 Apr 30;8. (3).
206. Karsh L, Du S, He J, Waters D, Muser E, Shore N. Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy. *Prostate*. 2024 Aug;84(11):1047-1055. Epub 2024 Apr 29.
207. Yue Z, Xue X, Qian J. The association between polypharmacy and health-related quality of life among older adults with prostate cancer. *J Geriatr Oncol*. 2024 Jun;15(5):101772. Epub 2024 Apr 26.
208. Tang Y, Gao Y, Zhang R, Li T, Yang Y, Huang L, Wei Y. A population-based propensity score matching analysis of risk factors and the impact on survival associated with refusal of cancer-directed surgery in patients with prostate cancer. *Sci Rep*. 2024 Apr 25;14(1):9494.
209. Morra S, Scheipner L, Baudo A, Jannello LMI, de Angelis M, Siech C, Goyal JA, Touma N, Tian Z, Saad F, Califano G, Di Bello F, La Rocca R, Ruvolo CC, Mangiapia F, Shariat SF, Ahyai S, Carmignani L, de Cobelli O, Musi G, Briganti A, Chun FKH, Longo N, Karakiewicz PI. Unmarried Status Effect on Stage at Presentation and Treatment Patterns in Non-Metastatic Upper Tract Urothelial Carcinoma Patients. *Clin Genitourin Cancer*. 2024 Aug;22(4):102105. Epub 2024 Apr 24.
210. Osman A, Nigro AR, Brauer SF, Borda LJ, Roberts AA. Epidemiology and primary location of melanoma in Asian patients: A surveillance, epidemiology, and end result-based study. *JAAD Int*. 2024 Apr 24;16:77-78. doi: 10.1016/j.jdin.2024.04.006. eCollection 2024 Sep.
211. Assad A, Barletta F, Incesu RB, Scheipner L, Morra S, Baudo A, Garcia CC, Tian Z, Ahyai S, Longo N, Chun FKH, Shariat SF, Tilki D, Briganti A, Saad F, Karakiewicz PI. Prognostic significance of lymph node count in surgically treated patients with T₂₋₄ stage nonmetastatic adrenocortical carcinoma. *Urol Oncol*. 2024 Aug;42(8):248.e1-248.e9. Epub 2024 Apr 23.
212. Basourakos SP, An A, Davuluri M, Pinheiro LC, Al Awamlh BAH, Borregales LD, Luan D, Tamimi RM, Hu JC, Kensler KH. Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer. *Urol Pract*. 2024 May;11(3):538-546. Epub 2024 Apr 19.
213. Filson CP, Richards TB, Ekwueme DU, Howard DH. Patterns of Care for Medicare Beneficiaries With Metastatic Prostate Cancer. *Urol Pract*. 2024 May;11(3):489-497. Epub 2024 Apr 19.
214. LeBlanc MR, Zhou X, Baggett CD, Tuchman SA, Jensen CE, Lichtman EI, Rubinstein SM. Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis. *Clin Lymphoma Myeloma Leuk*. 2024 Sep;24(9):611-620. Epub 2024 Apr 19.
215. Chang CY, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, Lo-Ciganic WH. Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors. *Br J Cancer*. 2024 Jun;130(12):1943-1950. Epub 2024 Apr 18.
216. Ribeiro-Dantas MDC, Li H, Cabeli V, Dupuis L, Simon F, Hettal L, Hamy AS, Isambert H. Learning interpretable causal networks from very large datasets, application to 400,000 medical records of breast cancer patients. *iScience*. 2024 Apr 16;27(5):109736. doi: 10.1016/j.isci.2024.109736. eCollection 2024 May 17.
217. Morra S, Scheipner L, Baudo A, Jannello LMI, de Angelis M, Siech C, Goyal JA, Touma N, Tian Z, Saad F, Shariat SF, Creta M, Califano G, Celentano G, Colla' Ruvolo C, Ahyai S,

- Carmignani L, de Cobelli O, Musi G, Briganti A, Chun FKH, Longo N, Karakiewicz PI. Contemporary conditional cancer-specific survival rates in surgically treated nonmetastatic primary urethral carcinoma. *J Surg Oncol*. 2024 Jun;129(7):1348-1353. Epub 2024 Apr 12.
218. Lee JM, To TM, Wang S, Lin CW, Johnson A, Meyer CS, Lee JS. Clinical and economic outcomes associated with lymph node examination status in early-stage non-small cell lung cancer: a real-world US study using the SEER-Medicare linked database. *Transl Cancer Res*. 2024 Apr 30;13(4):1821-1833. Epub 2024 Apr 10.
 219. Lyu HH, Lin JT, Wen YH. [Research progress of sinonasal malignant tumors based on SEER database]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*. 2024 Apr 7;59(4):392-398.
 220. Riviere P, Morgan KM, Deshler LN, Huang X, Marienfeld C, Coyne CJ, Rose BS, Murphy JD. Opioid tapering in older cancer survivors does not increase psychiatric or drug hospitalization rates. *J Natl Cancer Inst*. 2024 Apr 5;116(4):606-612.
 221. Allaire BT, Horvath ML, Lines LM, Davidoff AJ, Smith AW, Jensen RE. Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data. *Cancer Epidemiol Biomarkers Prev*. 2024 Apr 3;33(4):593-599.
 222. Dmukauskas M, Cioffi G, Waite KA, Sloan AE, Neff C, Price M, Ostrom QT, Barnholtz-Sloan JS. Sex differences in adverse events in Medicare individuals ≥ 66 years of age post glioblastoma treatment. *J Neurooncol*. 2024 May;168(1):111-123. Epub 2024 Apr 2.
 223. Burus T, Lei F, Huang B, Christian WJ, Hull PC, Ellis AR, Slavova S, Tucker TC, Lang Kuhs KA. Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic. *JAMA Oncol*. 2024 Apr 1;10(4):500-507.
 224. Dhir A, Rahul R, Liu Q, Pham D, Kronenfeld R, Koru-Sengul T, Pinheiro PS. Disparities in incidence and survival for patients with Ewing sarcoma in Florida. *Cancer Med*. 2024 Apr;13(8):e7151.
 225. Gordon MJ, Duan Z, Zhao H, Nastoupil L, Iyer S, Ferrajoli A, Danilov AV, Giordano SH. Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma. *JCO Clin Cancer Inform*. 2024 Apr;8:e2300223.
 226. Guo QH, Xie FC, Zhong FM, Wen W, Zhang XR, Yu XJ, Wang XL, Huang B, Li LP, Wang XZ. Application of interpretable machine learning algorithms to predict distant metastasis in ovarian clear cell carcinoma. *Cancer Med*. 2024 Apr;13(7):e7161.
 227. Ojukwu K, Eguchi MM, Adamson AS, Kerr KF, Piepkorn MW, Murdoch S, Barnhill RL, Elder DE, Knezevich SR, Elmore JG. Immunohistochemistry for Diagnosing Melanoma in Older Adults. *JAMA Dermatol*. 2024 Apr 1;160(4):434-440.
 228. Upshaw JN, Nelson J, Sweigart B, Rodday AM, Kumar AJ, Konstam MA, Wong JB, Ky B, Karmiy S, Friedberg JW, Evens AM, Kent DM, Parsons SK. Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma. *JACC CardioOncol*. 2024 Apr 16;6(2):200-213. doi: 10.1016/j.jacc.2024.02.003. eCollection 2024 Apr.
 229. Wagner MJ, Ravi V, Schaub SK, Kim EY, Sharib J, Mogal H, Park M, Tsai M, Duarte-Bateman D, Tufaro A, Loggers ET, Cranmer LD, Chau B, Hassett MJ, Grilley-Olson J, Paulson KG. Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020. *JAMA Netw Open*. 2024 Apr 1;7(4):e246235.
 230. Herbach EL, Curran M, Roberson ML, Carnahan RM, McDowell BD, Wang K, Lizarraga I, Nash SH, Charlton M. Guideline-concordant breast cancer care by patient race and ethnicity accounting for individual-, facility- and area-level characteristics: a SEER-Medicare study. *Cancer Causes Control*. 2024 Jul;35(7):1017-1031. Epub 2024 Mar 28.
 231. de Angelis M, Baudo A, Siech C, Jannello LMI, Di Bello F, Goyal JA, Tian Z, Longo N, de Cobelli O, Chun FKH, Saad F, Shariat SF, Carmignani L, Gandaglia G, Moschini M, Montorsi F, Briganti A, Karakiewicz PI. Non-Surgical Bladder-Sparing Multimodal Management in

- Organ-Confined Urothelial Carcinoma of the Urinary Bladder: A Population-Based Analysis. *Cancers (Basel)*. 2024 Mar 27;16. (7).
232. Zhu H, Zhao S, Zhao T, Chen L, Li S, Ji K, Jiang K, Tao H, Xuan J, Yang M, Xu B, Jiang M, Wang F. Comparison of metastasis and prognosis between early-onset and late-onset hepatocellular carcinoma: A population-based study. *Heliyon*. 2024 Mar 26;10(7):e28497. doi: 10.1016/j.heliyon.2024.e28497. eCollection 2024 Apr 15.
 233. Osazuwa-Peters OL, Deveaux A, Muehlbauer MJ, Ilkayeva O, Bain JR, Keku T, Berchuck A, Huang B, Ward K, Gates Kuliszewski M, Akinyemiju T. Racial Differences in Vaginal Fluid Metabolites and Association with Systemic Inflammation Markers among Ovarian Cancer Patients: A Pilot Study. *Cancers (Basel)*. 2024 Mar 23;16. (7).
 234. Donington J, Hu X, Zhang S, Song Y, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A. Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2024 Jul;25(5):440-448. Epub 2024 Mar 22.
 235. Lee MW, Anderson ZS, Girma AM, Klar M, Roman LD, Carlson JW, Wright JD, Sood AK, Matsuo K. Diagnosis Shift in Site of Origin of Tubo-Ovarian Carcinoma. *Obstet Gynecol*. 2024 May 1;143(5):660-669. Epub 2024 Mar 21.
 236. Truong B, Hornsby L, Fox B, Chou C, Zheng J, Qian J. Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database. *J Thromb Thrombolysis*. 2024 Apr;57(4):638-649. Epub 2024 Mar 20.
 237. Yu JB, DeStephano DM, Jeffers B, Horowitz DP, Soulos PR, Gross CP, Cheng SK. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. *J Clin Oncol*. 2024 Jun 1;42(16):1943-1952. Epub 2024 Mar 20.
 238. Truong B, Zheng J, Hornsby L, Fox B, Chou C, Qian J. Development and Validation of Machine Learning Algorithms to Predict 1-Year Ischemic Stroke and Bleeding Events in Patients with Atrial Fibrillation and Cancer. *Cardiovasc Toxicol*. 2024 Apr;24(4):365-374. Epub 2024 Mar 18.
 239. Liu YC, Schmidt RO, Kapadia NS, Phillips JD, Moen EL. Disparities in Access to Multidisciplinary Cancer Consultations and Treatment for Patients With Early-Stage Non-Small Cell Lung Cancer: A SEER-Medicare Analysis. *Int J Radiat Oncol Biol Phys*. 2024 Sep 1;120(1):102-110. Epub 2024 Mar 13.
 240. Lee MW, Vallejo A, Furey KB, Woll SM, Klar M, Roman LD, Wright JD, Matsuo K. Racial and ethnic differences in early death among gynecologic malignancy. *Am J Obstet Gynecol*. 2024 Aug;231(2):231.e1-231.e11. Epub 2024 Mar 7.
 241. Zhao X, Xu Z, Feng X. Clinical characteristics and prognoses in pediatric neuroblastoma with bone or liver metastasis: data from the SEER 2010-2019. *BMC Pediatr*. 2024 Mar 7;24(1):162.
 242. Ruiz JI, Lei X, Wu CF, Zhao H, Giordano SH, Rajan SS, Suarez-Almazor ME. Utilization of Biologic Disease-Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer. *Arthritis Care Res (Hoboken)*. 2024 Jun;76(6):850-859. Epub 2024 Mar 6.
 243. Chen S, He Y, Liu J, Wu R, Wang M, Jin A. Dynamic Survival Risk Prognostic Model and Genomic Landscape for Atypical Teratoid/Rhabdoid Tumors: A Population-Based, Real-World Study. *Cancers (Basel)*. 2024 Mar 5;16. (5).
 244. Panara K, Sangal N, Lakshmipathy D, Rajasekaran K. Survival Impact of Elective Neck Dissection and Adjuvant Radiation in N0 High-Grade Mucoepidermoid Carcinoma. *Otolaryngol Head Neck Surg*. 2024 Jul;171(1):138-145. Epub 2024 Mar 1.
 245. Little MP, Mai JZ, Fang M, Chernyavskiy P, Kennerley V, Cahoon EK, Cockburn MG, Kendall GM, Kimlin MG. Solar ultraviolet radiation exposure, and incidence of childhood

- acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based dataset. *Br J Cancer*. 2024 May;130(9):1441-1452. Epub 2024 Feb 29.
246. Tosakoon S, Lawrence WR, Shiels MS, Jackson SS. Sex Differences in Cancer Incidence Rates by Race and Ethnicity: Results from the Surveillance, Epidemiology, and End Results (SEER) Registry (2000-2019). *Cancers (Basel)*. 2024 Feb 29;16. (5).
 247. Harley RJ, Lyden M, Aribindi S, Socolovsky L, Harley EH Jr. Head and Neck Merkel Cell Carcinoma: Therapeutic Benefit of Adjuvant Radiotherapy for Nodal Disease. *Laryngoscope*. 2024 Aug;134(8):3587-3594. Epub 2024 Feb 24.
 248. Incesu RB, Barletta F, Tappero S, Piccinelli ML, Garcia CC, Morra S, Scheipner L, Tian Z, Saad F, Shariat SF, Ahyai S, Longo N, Chun FKH, de Cobelli O, Terrone C, Briganti A, Tilki D, Graefen M, Karakiewicz PI. Survival differences in non-seminoma testis cancer patients according to race/ethnicity. *Cancer Epidemiol*. 2024 Apr;89:102538. Epub 2024 Feb 20.
 249. Zhu Y. Incidence trend of neuroendocrine tumors and disparities by sex and race/ethnicity in adults from the United States, 2000-2020. *Eur J Cancer Prev*. 2024 Sep 1;33(5):475-484. Epub 2024 Feb 20.
 250. Arthur EK, Nikahd M, Hyer JM, Ridgway-Limle E, Nolan TS, Felix A, Xu M, Quick A, Paoletta C, Krok-Schoen JL. Associations of Demographic and Social Factors on Health-Related Quality-of-Life Changes Among Older Women With Breast or Gynecologic Cancer. *Oncol Nurs Forum*. 2024 Feb 19;51(2):127-141.
 251. Lee H, Hanson HA, Logan J, Maguire D, Kapadia A, Dewji S, Agasthya G. Evaluating county-level lung cancer incidence from environmental radiation exposure, PM_{2.5}, and other exposures with regression and machine learning models. *Environ Geochem Health*. 2024 Feb 17;46(3):82.
 252. Jiam ML, Xin KZ, Ha PK, Jiam NT. A supervised machine learning model for identifying predictive factors for recommending head and neck cancer surgery. *Head Neck*. 2024 May;46(5):1001-1008. Epub 2024 Feb 12.
 253. Franks JA, Davis ES, Bhatia S, Kenzik KM. Contribution of County Characteristics to Disparities in Rural Mortality After Cancer Diagnosis. *Am J Prev Med*. 2024 Jul;67(1):79-89. Epub 2024 Feb 9.
 254. Baum LVM, Kc M, Soulos PR, Jeffery MM, Ruddy KJ, Lerro CC, Lee H, Graham DJ, Rivera DR, Leapman MS, Jairam V, Dinan MA, Gross CP, Park HS. Trends in new and persistent opioid use in older adults with and without cancer. *J Natl Cancer Inst*. 2024 Feb 8;116(2):316-323.
 255. Howlader N, Bhattacharya M, Scoppa S, Miller D, Noone AM, Negoita S, Cronin K, Mariotto A. Cancer and COVID-19: US cancer incidence rates during the first year of the pandemic. *J Natl Cancer Inst*. 2024 Feb 8;116(2):208-215.
 256. Moen EL, Schmidt RO, Onega T, Brooks GA, O'Malley AJ. Association between a network-based physician linchpin score and cancer patient mortality: a SEER-Medicare analysis. *J Natl Cancer Inst*. 2024 Feb 8;116(2):230-238.
 257. Song M, Engels EA, Clarke MA, Kreimer AR, Shiels MS. Autoimmune disease and the risk of anal cancer in the US population aged 66 years and over. *J Natl Cancer Inst*. 2024 Feb 8;116(2):309-315.
 258. Yin Z, Wang M. Real-world study of lymphadenectomy in patients with advanced epithelial ovarian cancer. *J Obstet Gynaecol Res*. 2024 Apr;50(4):663-670. Epub 2024 Feb 8.
 259. Wu TC, Farrell MJ, Karimi-Mostowfi N, Chaballout BH, Akingbemi WO, Grogan TR, Raldow AC. Evaluating the Impact of Race and Ethnicity on Health-Related Quality of Life Disparities in Patients with Esophageal Cancer: A SEER-MHOS National Database Study. *Cancer Epidemiol Biomarkers Prev*. 2024 Feb 6;33(2):254-260.

260. Morra S, Scheipner L, Baudo A, Jannello LMI, de Angelis M, Siech C, Goyal JA, Touma N, Tian Z, Saad F, Califano G, Celentano G, la Rocca R, Napolitano L, Shariat SF, Ahyai S, Carmignani L, de Cobelli O, Musi G, Briganti A, Chun FKH, Longo N, Karakiewicz PI. Unmarried status effect on stage at presentation and treatment patterns in primary urethral carcinoma patients. *Urol Oncol*. 2024 May;42(5):161.e17-161.e23. Epub 2024 Feb 5.
261. Jensen CE, Kuo TM, LeBlanc MR, Baggett CD, Duchesneau ED, Zhou X, Reeder-Hayes KE, Lund JL. Functional Status Associations With Treatment Receipt and Outcomes Among Older Adults Newly Diagnosed With Multiple Myeloma. *JCO Clin Cancer Inform*. 2024 Feb;8:e2300214.
262. Lobo N, Duan Z, Sood A, Tan WS, Grajales V, Contieri R, Lindsborg SV, Dyrskjøl L, Zhao H, Giordano SH, Williams SB, Bree KK, Kamat AM. Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? *Eur Urol Oncol*. 2024 Oct;7(5):1069-1079. Epub 2024 Feb 1.
263. Ailawadhi S, Ravelo A, Ng CD, Shah B, Lamarre N, Wang R, Eakle K, Biondo JM. Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA. *J Comp Eff Res*. 2024 Feb;13(2):e230119. Epub 2024 Jan 31.
264. Kaplan-Marans E, Zhang TR, Hu JC. Oncologic Outcomes of Testosterone Therapy for Men on Active Surveillance for Prostate Cancer: A Population-based Analysis. *Eur Urol Open Sci*. 2024 Jan 31;60:36-43. doi: 10.1016/j.euros.2024.01.005. eCollection 2024 Feb.
265. Wang S, Ning J, Xu Y, Shih YT, Shen Y, Li L. Longitudinal varying coefficient single-index model with censored covariates. *Biometrics*. 2024 Jan 29;80. (1).
266. Amboree TL, Damgacioglu H, Sonawane K, Adsul P, Montealegre JR, Deshmukh AA. Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county-level income in the United States, 2000-2019. *Int J Cancer*. 2024 May 1;154(9):1549-1555. Epub 2024 Jan 25.
267. Ochoa Scussiatto H, Stenson KM, Al-Khudari S, Jelinek MJ, Pinto JM, Bhayani MK. Air pollution is associated with increased incidence-rate of head and neck cancers: A nationally representative ecological study. *Oral Oncol*. 2024 Mar;150:106691. Epub 2024 Jan 23.
268. Sun J, Wang M, Kan Z. Diagnostic and prognostic risk factors analysis for distant metastasis in melanoma: a population-based study. *Eur J Cancer Prev*. 2024 Sep 1;33(5):461-474. Epub 2024 Jan 23.
269. Troester A, Kohn J, Wang Q, Weaver L, Hassan I, Gaertner W, Marmor S, Goffredo P. Management and staging of anal adenocarcinoma in the United States: a population-based analysis. *J Gastrointest Surg*. 2024 Apr;28(4):519-527. Epub 2024 Jan 23.
270. Morra S, Scheipner L, Baudo A, Jannello LMI, de Angelis M, Siech C, Goyal JA, Touma N, Tian Z, Saad F, Califano G, Creta M, Celentano G, Shariat SF, Ahyai S, Carmignani L, de Cobelli O, Musi G, Briganti A, Chun FKH, Longo N, Karakiewicz PI. The Association between Urinary Diversion Type and Other-Cause Mortality in Radical Cystectomy Patients. *Cancers (Basel)*. 2024 Jan 19;16. (2).
271. Hujoel IA, Hujoel MLA. The Rising Incidence and Poor Outcomes of Enteropathy-Associated T-Cell Lymphoma. *Am J Gastroenterol*. 2024 Jul 1;119(7):1412-1416. Epub 2024 Jan 18.
272. Black AK, Kahn AE, Lamy C, Warman R, Barengo NC. The association between race and age of diagnosis of retinoblastoma in United States children. *J AAPOS*. 2024 Feb;28(1):103810. Epub 2024 Jan 17.
273. Wang R, Neparidze N, Ma X, Colditz GA, Chang SH, Wang SY. Racial differences in treatment and survival among older patients with multiple myeloma. *Cancer Med*. 2024 Feb;13(3):e6915. Epub 2024 Jan 17.
274. Fromer MW, Xu Q, Shindorf ML, Mouw TJ, Kong M, Myers J, Feygin Y, Ghosh I, Martin RCG 2nd, McMasters KM, Philips P, Scoggins CR, Ellis CT, Egger ME. Diagnosis of

- Pancreatic Cancer after Cholecystectomy in the Elderly. *Am Surg*. 2024 Jun;90(6):1195-1201. Epub 2024 Jan 11.
275. Hashibe M, Wei M, Lee CJ, Tao R, Koric A, Wang J, Daud A, Tay D, Shen J, Lee YA, Chang CE. Incident Cardiovascular Disease Risk among Older Asian, Native Hawaiian and Pacific Islander Breast Cancer Survivors. *Cancer Epidemiol Biomarkers Prev*. 2024 Jan 9;33(1):126-135.
 276. Chang CY, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, Lo-Ciganic WH. Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors. *Breast Cancer Res Treat*. 2024 Apr;204(3):561-577. Epub 2024 Jan 8.
 277. Yin Y, Wang L, Huang C. Surgery combined with adjuvant radiation and chemotherapy prolonged overall survival in stage IVC anaplastic thyroid cancer: a SEER-based analysis. *Endocrine*. 2024 Jul;85(1):250-257. Epub 2024 Jan 6.
 278. Wang Y, Ge L, Cai Y. The novel predictive nomograms for early death in metastatic hepatocellular carcinoma: A large cohort study. *Medicine (Baltimore)*. 2024 Jan 5;103(1):e36812.
 279. Aslani A, Soheili A, Mousavi SE, Ebrahimi A, Antar RM, Yekta Z, Nejadghaderi SA. Incidence trends of gastric cancer in the United States over 2000-2020: A population-based analysis. *PLoS One*. 2024 Sep 25;19(9):e0310040. doi: 10.1371/journal.pone.0310040. eCollection 2024.
 280. Battiwalla M, Chao JH, Cox T, Cruz JC, Donnellan WB, Eghtedar A, Kambhampati S, Malik S, Maris MB, Rotta M, Slovick FT, Ramakrishnan A, Bhushan V, Sears L, Martin C, Holder J, Junglen A, Majhail N, LeMaistre CF. Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting. *Clin Hematol Int*. 2024 Oct 9;6(4):43-52. doi: 10.46989/001c.124273. eCollection 2024.
 281. Danese MD, Balasubramanian A, Bebb DG, Pundole X. Development of an algorithm to identify small cell lung cancer patients in claims databases. *Front Oncol*. 2024 Aug 15;14:1358562. doi: 10.3389/fonc.2024.1358562. eCollection 2024.
 282. Dulaney A, Virostko J. Disparities in the Demographic Composition of The Cancer Imaging Archive. *Radiol Imaging Cancer*. 2024 Jan;6(1):e230100.
 283. Fu T, Mao C, Chen Z, Huang Y, Li H, Wang C, Liu J, Li S, Lin F. Disease characteristics and clinical specific survival prediction of spinal ependymoma: a genetic and population-based study. *Front Neurol*. 2024 Sep 13;15:1454061. doi: 10.3389/fneur.2024.1454061. eCollection 2024.
 284. Ghali F, Holt SK, Koehne EL, Chen JJ, Weg ES, Liao JJ, Zeng J, Grivas P, Hawley JE, Hsieh AC, Montgomery RB, Wright JL. Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older. *Front Oncol*. 2024 May 15;14:1341655. doi: 10.3389/fonc.2024.1341655. eCollection 2024.
 285. Jiang J, Shiels MS, Rivera D, Ghany MG, Engels EA, O'Brien TR. Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans. *PLoS One*. 2024 Nov 1;19(11):e0307746. doi: 10.1371/journal.pone.0307746. eCollection 2024.
 286. Jiang R, Wang T, Liu Y, Kumar A, Shen P, Fukunaga-Kalabis M, Ayyagari R. The economic burden of recurrence in elderly patients with completely resected, stage IIB/IIC or III melanoma: an analysis of the Surveillance, Epidemiology, and End Results-Medicare linked database. *J Med Econ*. 2024 Jan-Dec;27(1):1279-1292. Epub 2024 Oct 2.
 287. Kim U, Koroukian S, Rose J, Hoehn RS, Carroll BT. US Cancer Detection Decreased Nearly 9 Percent During The First Year Of The COVID-19 Pandemic. *Health Aff (Millwood)*. 2024 Jan;43(1):125-130.
 288. Knapp BJ, Cittolin-Santos GF, Flanagan ME, Grandhi N, Gao F, Samson PP, Govindan R, Morgensztern D. Incidence and risk factors for bone metastases at presentation in solid

- tumors. *Front Oncol.* 2024 May 10;14:1392667. doi: 10.3389/fonc.2024.1392667. eCollection 2024.
289. Liu Z, Xu Q, Xia H, Wang M. Dynamic estimates of survival of patients with poorly differentiated thyroid carcinoma: a population-based study. *Front Endocrinol (Lausanne).* 2024 Sep 13;15:1375274. doi: 10.3389/fendo.2024.1375274. eCollection 2024.
 290. Liu Z, Jing C, Hooblal YM, Yang H, Chen Z, Kong F. Construction and validation of log odds of positive lymph nodes (LODDS)-based nomograms for predicting overall survival and cancer-specific survival in ovarian clear cell carcinoma patients. *Front Oncol.* 2024 Mar 21;14:1370272. doi: 10.3389/fonc.2024.1370272. eCollection 2024.
 291. Ma J, Groisberg R, Shao C, Zhong W. Incidence of Undifferentiated Pleomorphic Sarcoma (UPS) in the United States. *Sarcoma.* 2024 Oct 29;2024:6735002. doi: 10.1155/2024/6735002. eCollection 2024.
 292. Mbous YPV, Siddiqui ZA, Bharmal M, LeMasters T, Kolodney J, Kelley GA, Kamal KM, Sambamoorthi U. Predictive and Interpretable Machine Learning of Economic Burden: The Role of Chronic Conditions Among Elderly Patients with Incident Primary Merkel Cell Carcinoma (MCC). *Clinicoecon Outcomes Res.* 2024 Dec 11;16:847-868. doi: 10.2147/CEOR.S456968. eCollection 2024.
 293. Mousavi SE, Ilaghi M, Mahdavizadeh V, Ebrahimi R, Aslani A, Yekta Z, Nejadghaderi SA. A population-based study on incidence trends of small intestine cancer in the United States from 2000 to 2020. *PLoS One.* 2024 Aug 19;19(8):e0307019. doi: 10.1371/journal.pone.0307019. eCollection 2024.
 294. Pankratz VS, Kanda D, Kosich M, Edwardson N, English K, Adsul P, Mishra SI. Racial and Ethnic Disparities in Colorectal Cancer Incidence Trends Across Regions of the United States From 2001 to 2020 - A United States Cancer Statistics Analysis. *Cancer Control.* 2024 Jan-Dec;31:10732748241300653.
 295. Prabhu VS, Kponee-Shovein K, Cheng M, Hong JL, Song Y, Sun Y, Hilts A, Hua Q, Lichfield J, Duska LR. Real-world perioperative treatment patterns and burden of recurrent disease in patients with high-risk endometrial cancer: a SEER-Medicare study. *J Med Econ.* 2024 Jan-Dec;27(1):1410-1420. Epub 2024 Nov 1.
 296. Qin L, Tian J, Zhang Y, Yin Y, Dou Z, Chen J, Zhang Z, Gong Y, Fu W. Comparison of postoperative survival prognosis between early-onset and late-onset esophageal cancer: A Population-based study. *PLoS One.* 2024 Dec 12;19(12):e0315391. doi: 10.1371/journal.pone.0315391. eCollection 2024.
 297. Rong Y, Ramachandran S, Bhattacharya K, Yang Y, Earl S, Chang Y, Bentley JP. The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC. *Immunotherapy.* 2024;16(16-17):1057-1068. Epub 2024 Sep 13.
 298. Rong Y, Bentley JP, Bhattacharya K, Yang Y, Chang Y, Earl S, Ramachandran S. Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer. *Cancer Med.* 2024 Jan;13(1):e6879. Epub 2024 Jan 2.
 299. Semprini JT. Late-Stage Oral Cancer Detection After California and Illinois Restored Medicaid Dental Benefits. *OTO Open.* 2024 Jan 16;8(1):e111. doi: 10.1002/oto2.111. eCollection 2024 Jan-Mar.
 300. Vu L, Koroukian SM, Douglas SL, Fein HL, Warner DF, Schiltz NK, Cullen J, Owusu C, Sajatovic M, Rose J, Martin R. Understanding the Utility of Less Than Six-Month Prognosis Using Administrative Data Among U.S. Nursing Home Residents With Cancer. *Palliat Med Rep.* 2024 Mar 28;5(1):127-135. doi: 10.1089/pmr.2023.0047. eCollection 2024.
 301. Wang B, Chen X, Li R, Ai B, Ye F, Zhao J, Zhang Y, Huang Z, Li Z, Bi X, Zhao H, Cao D, Cai J, Zhou J, Yan T. Comprehensive evaluation of clinical outcomes in hepatic epithelioid hemangioendothelioma subsets: insights from SEER Database and departmental cohort

- analysis. *Front Immunol.* 2024 Oct 22;15:1491922. doi: 10.3389/fimmu.2024.1491922. eCollection 2024.
302. Wu Y, Gu W, Du B, Lv C, Yao N, Zhu Y, Ouyang J, Lai J. Impact of the number of lymph node dissections and a novel risk stratification on the prognosis in elderly locally advanced esophageal adenocarcinoma. *J Cancer.* 2024 Jun 3;15(13):4197-4204. doi: 10.7150/jca.96574. eCollection 2024.
 303. Yang AB, Mhango G, Kong CY, Lin JJ, Wisnivesky JP, Leiter A. Statin prescription disparities in patients with breast cancer and diabetes for primary cardiovascular disease prevention. *Front Oncol.* 2024 Nov 6;14:1483918. doi: 10.3389/fonc.2024.1483918. eCollection 2024.
 304. Yang D, Karanth SD, Yoon HS, Yang JJ, Lou X, Bian J, Zhang D, Guo Y, Yaghjian L, Akinyemiju T, Rodriguez E, Mehta HJ, Braithwaite D. Disparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis. *JCO Oncol Adv.* 2024 Dec 3;1:e2400008. doi: 10.1200/OA.24.00008. eCollection 2024.
 305. Yang J, Li S, Zhao Y, Yang F, Wang Q, Ding L, Chen C, Chu X. The impact of tumor size on the prognosis and chemotherapy efficacy in stage I/II colon cancer patients. *J Cancer.* 2024 Jul 22;15(15):5020-5027. doi: 10.7150/jca.95743. eCollection 2024.
 306. Zhang J, Lin Y, Zhou J, Geng R, Zheng Z, Guo C, Ma X, Li S. Enhanced Survival with Lymphadenectomy in Early-Stage Metachronous Second Primary Lung Cancer: A Retrospective Analysis. *Oncol Res Treat.* 2024;47(5):198-205. Epub 2024 Mar 15.
 307. Zhao T, Jia W, Zhao C, Wu Z. Survival benefit of surgery for second primary esophageal cancer following gastrointestinal cancer: a population-based study. *J Gastrointest Surg.* 2024 Jan;28(1):1-9.
 308. Teng Y, Xia C, Cao M, Yang F, Yan X, He S, Cao M, Zhang S, Li Q, Tan N, Wang J, Chen W. Lung cancer burden and trends from 2000 to 2018 in China: Comparison between China and the United States. *Chin J Cancer Res.* 2023 Dec 30;35(6):618-626.
 309. Hong YD, Enewold L, Halpern MT, Zeruto C, Mariotto AB. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication. *Pharmacoepidemiol Drug Saf.* 2024 Jan;33(1):e5745. Epub 2023 Dec 29.
 310. Navarro S, Tsui J, Barzi A, Stern MC, Pickering T, Farias AJ. Associations Between Patient Experience With Care, Race and Ethnicity, and Receipt of CRC Treatment Among SEER-CAHPS Patients With Multiple Comorbidities. *J Natl Compr Canc Netw.* 2023 Dec 27;22(1D):e237074.
 311. Hansen AR, Vardell VA, Fitzgerald LA. Epidemiologic Characteristics, Treatment Patterns, and Survival Analysis of Plasmablastic Lymphoma in the United States: A SEER and NCDB Analysis. *Clin Lymphoma Myeloma Leuk.* 2024 Apr;24(4):e152-e160.e3. Epub 2023 Dec 25.
 312. Wang W, Wang X, Che G, Qiao J, Chen Z, Liu J. The Establishment and Verification of a Nomogram Model for Predicting the Overall Survival of Medullary Thyroid Carcinoma: An Analysis Based on the SEER Database. *Curr Oncol.* 2023 Dec 22;31(1):84-96.
 313. Baudo A, Morra S, Scheipner L, Jannello LMI, de Angelis M, Siech C, Touma N, Goyal JA, Tian Z, Acquati P, Longo N, Ahyai S, de Cobelli O, Briganti A, Chun FKH, Saad F, Shariat SF, Carmignani L, Karakiewicz PI. The effect of married status on cancer-specific mortality in nonmetastatic pelvic liposarcoma patients according to sex. *World J Surg.* 2024 Jan;48(1):97-103. Epub 2023 Dec 18.
 314. Berger E, Long JB, Sheffrin M, Lindsay M, Richman IB. Use of surveillance mammography among older patients with a history of breast cancer. *J Geriatr Oncol.* 2024 Apr;15(3):101686. Epub 2023 Dec 18.

315. Byun JY, Han S, Qdaisat A, Park C. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer. *Expert Opin Drug Saf.* 2024 Aug;23(8):1007-1015. Epub 2023 Dec 18.
316. Zheng Z, Shi KS, Kamal A, Howard DH, Horný M, Richards TB, Ekwueme DU, Yabroff KR. Health-related quality of life among prostate cancer survivors with metastatic disease and non-metastatic disease and men without a cancer history in the USA. *J Cancer Surviv.* 2025 Jun;19(3):871-883. Epub 2023 Dec 16.
317. Morra S, Scheipner L, Baudo A, Jannello LMI, de Angelis M, Siech C, Goyal JA, Touma N, Tian Z, Saad F, Creta M, Califano G, Celentano G, Shariat SF, Ahyai S, Carmignani L, de Cobelli O, Musi G, Briganti A, Chun FKH, Longo N, Karakiewicz PI. Contemporary sex-specific analysis of the association of marital status with cancer-specific mortality in primary urethral carcinoma patients. *Urol Oncol.* 2024 Feb;42(2):31.e1-31.e8. Epub 2023 Dec 14.
318. Guo X, Xia H, Zhang F, Hao G. Real-world progression in the survival of de novo Metastatic prostate cancer over the past decade. *Urol Oncol.* 2024 Mar;42(3):68.e1-68.e9. Epub 2023 Dec 13.
319. Donington J, Hu X, Zhang S, Song Y, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A. Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy. *J Thorac Cardiovasc Surg.* 2024 Oct;168(4):1261-1269.e1. Epub 2023 Dec 12.
320. Xu X, Chen L, Nunez-Smith M, Clark M, Ferris JS, Hershman DL, Wright JD. Black-White differences in uterine cancer symptomatology and stage at diagnosis. *Gynecol Oncol.* 2024 Jan;180:118-125. Epub 2023 Dec 12.
321. Fong ZV, Severs G, Moir J, White S, Qadan M, Tingle S. Calcium channel blockers are associated with improved survival in pancreatic cancer patients undergoing neoadjuvant chemotherapy and resection. *HPB (Oxford).* 2024 Mar;26(3):418-425. Epub 2023 Dec 10.
322. Monterroso PS, Li Z, Domingues AM, Sample JM, Marcotte EL. Racial and ethnic and socioeconomic disparities in childhood cancer incidence trends in the United States, 2000-2019. *J Natl Cancer Inst.* 2023 Dec 6;115(12):1576-1585.
323. Allen JM, Awunti M, Guo Y, Bian J, Rogers SC, Scarton L, DeRemer DL, Wilkie DJ. Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies. *Cancer Epidemiol Biomarkers Prev.* 2023 Dec 1;32(12):1675-1682.
324. Ma TM, Agarwal N, Mahal B, Barragan-Carrillo R, Spratt D, Rettig MB, Valle LF, Steinberg ML, Garraway I, Vapiwala N, Xiang M, Kishan AU. Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer. *JAMA Netw Open.* 2023 Dec 1;6(12):e2345906.
325. Winn AN, Atallah E, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. *JAMA Netw Open.* 2023 Dec 1;6(12):e2347950.
326. Zhou SN, Jv DW, Meng XF, Zhang JJ, Liu C, Wu ZY, Hong N, Lu YY, Zhang N. Feasibility of machine learning-based modeling and prediction using multiple centers data to assess intrahepatic cholangiocarcinoma outcomes. *Ann Med.* 2023 Dec;55(1):215-223.
327. Nudelman NT, Ekhaton N, Rothschild M, Wladis EJ. A SEER program study of survival trends in Merkel cell carcinoma of the eyelid: 2000-2019. *Orbit.* 2024 Jun;43(3):290-295. Epub 2023 Nov 30.
328. Adrianzen-Herrera D, Sparks AD, Singh R, Alejos-Castillo D, Batra A, Glushakow-Smith S, Pradhan K, Shastri A, Zakai NA. Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis. *Blood Adv.* 2023 Nov 28;7(22):6913-6922.

329. Mousavi SE, Ilaghi M, Aslani A, Yekta Z, Nejadghaderi SA. A population-based study on incidence trends of myeloma in the United States over 2000-2020. *Sci Rep*. 2023 Nov 24;13(1):20705.
330. Liao H, Tang C, Zhou Z, Shi H, Li T, Liang Y, Li M, Li T, Lei X. Adjuvant Radiotherapy Is Not Necessary for Stage III Mucinous Rectal Cancer: Evidence Based on Long Survival Analysis from SEER Data. *J Gastrointest Surg*. 2023 Dec;27(12):2857-2866. Epub 2023 Nov 21.
331. Ye Y, Zheng Y, Li J, Miao Q, Lin M, Chen J, Ruan H, Zhang X. Endoscopic excision versus radical nephroureterectomy for non-muscle invasive upper tract urothelial carcinoma: A population-based large cohort study. *Heliyon*. 2023 Nov 17;9(12):e22408. doi: 10.1016/j.heliyon.2023.e22408. eCollection 2023 Dec.
332. Schafer EJ, Islami F, Han X, Nogueira LM, Wagle NS, Yabroff KR, Sung H, Jemal A. Changes in cancer incidence rates by stage during the COVID-19 pandemic in the US. *Int J Cancer*. 2024 Mar 1;154(5):786-792. Epub 2023 Nov 16.
333. Sodagum L, Passarelli R, Pfail J, Patel HV, Chua K, Doppalapudi SK, Golombos D, Elsamra SE, Singer EA, Jang TL, Srivastava A, Ghodoussipour S. Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer. *Urol Oncol*. 2024 Jan;42(1):21.e9-21.e20. Epub 2023 Nov 10.
334. Siegel DA, King JB, Lupo PJ, Durbin EB, Tai E, Mills K, Van Dyne E, Buchanan Lunsford N, Henley SJ, Wilson RJ. Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019. *J Natl Cancer Inst*. 2023 Nov 8;115(11):1337-1354.
335. Charalel RA, Mushlin AI, Zheng X, Mao J, Carlos R, Brown RS Jr, Fortune BE, Talenfeld AD, Madoff DC, Ibrahim S, Johnson MS, Sedrakyan A. Predictors for Early Liver Cancer Survival After Ablation and Surgical Resection: A Surveillance, Epidemiology, and End Results Program-Medicare Study. *J Am Coll Radiol*. 2024 Feb;21(2):295-308. Epub 2023 Nov 2.
336. Wong LY, Kapula N, He H, Guenthart BA, Vitzthum LK, Horst K, Liou DZ, Backhus LM, Lui NS, Berry MF, Shrager JB, Elliott IA. Risk of developing subsequent primary lung cancer after receiving radiation for breast cancer. *JTCVS Open*. 2023 Oct 31;16:919-928. doi: 10.1016/j.xjon.2023.10.031. eCollection 2023 Dec.
337. Zeidan AM, Mearns ES, Ng CD, Shah A, Lamarre N, Yellow-Duke A, Alrawashdh N, Yang B, Cheng WH, Bui CN, Svensson A. Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs). *Clin Lymphoma Myeloma Leuk*. 2024 Mar;24(3):177-186. Epub 2023 Oct 30.
338. Zhu S, Tu J, Pei W, Zheng Z, Bi J, Feng Q. Development and validation of prognostic nomograms for early-onset colon cancer in different tumor locations: a population-based study. *BMC Gastroenterol*. 2023 Oct 21;23(1):362.
339. Gera K, Kahramangil D, Fenton GA, Martir D, Rodriguez DN, Ijaz Z, Lin RY, Rogers SC, Ramnaraigh BH, George TJ, Hong YR, Hughes SJ, Nassour I, Sahin I. Prognosis and Treatment Outcomes of Bone Metastasis in Gallbladder Adenocarcinoma: A SEER-Based Study. *Cancers (Basel)*. 2023 Oct 19;15. (20).
340. Li S, Yi H, Leng Q, Wu Y, Mao Y. New perspectives on cancer clinical research in the era of big data and machine learning. *Surg Oncol*. 2024 Feb;52:102009. Epub 2023 Oct 16.
341. Kentros PA, Huang Y, Wylie BJ, Khoury-Collado F, Hou JY, de Meritens AB, St Clair CM, Hershman DL, Wright JD. Ambient particulate matter air pollution exposure and ovarian cancer incidence in the USA: An ecological study. *BJOG*. 2024 Apr;131(5):690-698. Epub 2023 Oct 15.
342. Chang A, Flores RM, Taioli E. Unequal racial distribution of immunotherapy for late-stage non-small cell lung cancer. *J Natl Cancer Inst*. 2023 Oct 9;115(10):1224-1226.
343. Katayama ES, Woldesenbet S, Munir MM, Endo Y, Moazzam Z, Lima HA, Shaikh CF, Pawlik TM. Poor Access to Mental Healthcare is Associated with Worse Postoperative

- Outcomes Among Patients with Gastrointestinal Cancer. *Ann Surg Oncol*. 2024 Jan;31(1):49-57. Epub 2023 Oct 9.
344. Warren JL, Parsons HM, Mariotto AB, Boyd E, Enewold L. Evaluation of the Completeness of Managed Care Data to Identify Cancer Diagnoses and Treatments for Patients in the SEER-Medicare Data. *Med Care*. 2023 Dec 1;61(12):846-857. Epub 2023 Oct 4.
 345. Yeung E, Satchell EK, Patel AS, McElhaney N. Socioeconomic Factors Associated With Thymoma Survival in the United States. *J Surg Res*. 2024 Jan;293:223-230. Epub 2023 Oct 3.
 346. Herbach EL, Nash SH, Lizarraga IM, Carnahan RM, Wang K, Ogilvie AC, Curran M, Charlton ME. Patterns of Evidence-Based Care for the Diagnosis, Staging, and First-line Treatment of Breast Cancer by Race-Ethnicity: A SEER-Medicare Study. *Cancer Epidemiol Biomarkers Prev*. 2023 Oct 2;32(10):1312-1322.
 347. O'Brien TR, Devesa SS, Koshiol J, Marrero JA, Shiels MS. Decreasing incidence of hepatocellular carcinoma among most racial groups: SEER-22, 2000-2019. *Cancer Med*. 2023 Oct;12(19):19960-19967. Epub 2023 Sep 30.
 348. Price M, Ryan K, Shoaf ML, Neff C, Iorgulescu JB, Landi DB, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS, Ostrom QT. Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015-2019. *Neurooncol Pract*. 2023 Sep 28;11(1):5-25. doi: 10.1093/nop/npad061. eCollection 2024 Feb.
 349. Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, Kantarjian H. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. *Cancer*. 2023 Dec 1;129(23):3805-3814. Epub 2023 Sep 28.
 350. Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Baudo A, Tian Z, Parodi S, Dell'Oglio P, Briganti A, de Cobelli O, Chun FKH, Graefen M, Longo N, Ahyai S, Carmignani L, Saad F, Shariat SF, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Survival of patients with clear cell renal carcinoma according to number and location of organ-specific metastatic sites. *Urol Oncol*. 2024 Jan;42(1):22.e23-22.e31. Epub 2023 Sep 28.
 351. Dibble KE, Deng Z, Jin M, Connor AE. Associations between race/ethnicity and SEER-CAHPS patient care experiences among female Medicare beneficiaries with breast cancer. *J Geriatr Oncol*. 2023 Nov;14(8):101633. Epub 2023 Sep 22.
 352. Mahashabde R, Bhatti SA, Martin BC, Painter JT, Rodriguez A, Ying J, Li C. Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain Metastases. *JCO Oncol Pract*. 2023 Nov;19(11):1009-1019. Epub 2023 Sep 20.
 353. Chaves N, Broekhuis JM, Fligor SC, Collins RA, Modest AM, Kaul S, James BC. Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: A SEER-Medicare Analysis. *J Clin Endocrinol Metab*. 2023 Sep 18;108(10):2589-2596.
 354. Gordon MJ, Duan Z, Zhao H, Nastoupil L, Ng S, Danilov AV, Iyer S, Giordano SH. Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma. *Leuk Lymphoma*. 2023 Dec;64(14):2258-2268. Epub 2023 Sep 14.
 355. Morra S, Incesu RB, Scheipner L, Baudo A, Jannello LMI, de Angelis M, Siech C, Goyal JA, Tian Z, Saad F, Califano G, la Rocca R, Capece M, Shariat SF, Ahyai S, Carmignani L, de Cobelli O, Musi G, Tilki D, Briganti A, Chun FKH, Longo N, Karakiewicz PI. Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis. *Cancers (Basel)*. 2023 Sep 10;15. (18).

356. Doshi SD, DeStephano D, Accordini MK, Elkin E, Raghunathan RR, Wright JD, Hershman DL. Disparities with influenza vaccine use in long-term survivors of metastatic breast cancer. *Breast Cancer Res Treat.* 2024 Jan;203(1):111-119. Epub 2023 Sep 9.
357. Choi YM, Kim MJ, Lee J, Kwak MK, Jeon MJ, Kim TY, Hong EG, Kim WB, Kim WG. Long-Term Changes in the Mortality Rates of Thyroid Cancer in Korea: Analysis of Korean National Data from 1985 to 2020. *Endocrinol Metab (Seoul).* 2023 Oct;38(5):588-595. Epub 2023 Sep 8.
358. Mariotto AB, Feuer EJ, Howlader N, Chen HS, Negoita S, Cronin KA. Interpreting cancer incidence trends: challenges due to the COVID-19 pandemic. *J Natl Cancer Inst.* 2023 Sep 7;115(9):1109-1111.
359. Anderson T, Herrera D, Mireku F, Barner K, Kokkinakis A, Dao H, Webber A, Merida AD, Gallo T, Pierobon M. Geographical Variation in Social Determinants of Female Breast Cancer Mortality Across US Counties. *JAMA Netw Open.* 2023 Sep 5;6(9):e2333618.
360. Chen X, Chen Y, Xiao F, Liu M, Gu Z, Li Y, Hong M. Survival and analysis of prognostic factors for primary malignant cardiac tumors based on the SEER database. *J Cancer Res Clin Oncol.* 2023 Nov;149(17):15687-15696. Epub 2023 Sep 4.
361. Apple J, DerSarkissian M, Shah A, Chang R, Chen Y, He X, Chun J. Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs. *J Comp Eff Res.* 2023 Nov;12(11):e230107. Epub 2023 Sep 1.
362. Holman DM, King JB, White A, Singh SD, Lichtenfeld JL. Acral lentiginous melanoma incidence by sex, race, ethnicity, and stage in the United States, 2010-2019. *Prev Med.* 2023 Oct;175:107692. Epub 2023 Sep 1.
363. Podoltsev NA, Wang R, Shallis RM, Stempel JM, Di M, Neparidze N, Zeidan AM, Huntington SF, Giri S, Hull SC, Gore SD, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. *Cancer Med.* 2023 Sep;12(18):18889-18900. Epub 2023 Sep 13.
364. Wang J, Zhang S, Yi H, Ma S. Comparative Effectiveness Analysis of Lumpectomy and Mastectomy for Elderly Female Breast Cancer Patients: A Deep Learning-based Big Data Analysis. *Yale J Biol Med.* 2023 Sep 29;96(3):327-346. doi: 10.59249/IAJU7580. eCollection 2023 Sep.
365. Xu B, Zhang F, Wu R, Peng Y, Mao Z, Tong S. Incidence, survival, and prognostic factors for patients with gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms: a SEER population-based study. *J Cancer Res Clin Oncol.* 2023 Nov;149(17):15657-15669. Epub 2023 Sep 1.
366. Kilic S, Zhao J, Okut H, Jani CT, Radwan A, Dudipala H, Burns L, Tapan U. Disparities in US Lung Cancer Clinical Trial Enrollment. *J Racial Ethn Health Disparities.* 2024 Oct;11(5):3201-3209. Epub 2023 Aug 31.
367. Wieder R, Adam N. Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data. *Cancers (Basel).* 2023 Aug 30;15. (17).
368. El Khoury CJ, Clouston SAP. Racial/Ethnic Disparities in Prostate Cancer 5-Year Survival: The Role of Health-Care Access and Disease Severity. *Cancers (Basel).* 2023 Aug 27;15. (17).
369. Zheng D, Thomas J 3rd. Adherence to and persistence with adjuvant hormone therapy, healthcare utilization, and healthcare costs among older women with breast cancer: A population-based longitudinal cohort study. *J Geriatr Oncol.* 2023 Nov;14(8):101599. Epub 2023 Aug 18.
370. Burke JM, Masaquel A, Wang R, Hossain F, Li J, Zhou SQ, Ng CD, Matasar M. Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. *Clin Lymphoma Myeloma Leuk.* 2023 Nov;23(11):e393-e404. Epub 2023 Aug 9.

371. Barnes JM, Johnson KJ, Osazuwa-Peters N, Yabroff KR, Chino F. Changes in cancer mortality after Medicaid expansion and the role of stage at diagnosis. *J Natl Cancer Inst.* 2023 Aug 8;115(8):962-970.
372. Li Z, Li W, Xue L. Primary pulmonary hyalinizing clear cell carcinoma with vocal-cord squamous cell carcinoma: a case report with systematic review. *Diagn Pathol.* 2023 Aug 8;18(1):90.
373. Richman IB, Long JB, Soulos PR, Wang SY, Gross CP. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. *Ann Intern Med.* 2023 Sep;176(9):1172-1180. Epub 2023 Aug 8.
374. Liu YS, Liu Y, Park C. Association of cardiovascular disease with health-related quality of life among older women with early-stage breast cancer undergoing adjuvant endocrine therapy. *J Geriatr Oncol.* 2023 Sep;14(7):101598. Epub 2023 Aug 5.
375. Roy AM, George A, Attwood K, Alaklabi S, Patel A, Omilian AR, Yao S, Gandhi S. Effect of neighborhood deprivation index on breast cancer survival in the United States. *Breast Cancer Res Treat.* 2023 Nov;202(1):139-153. Epub 2023 Aug 5.
376. Yang S, Chang W, Zhang B, Hou Q, Zhang B, Kang Y, Yin Y, Wan J, Shang P. Development and validation of a predictive model for penile cancer based on the surveillance, epidemiology, and end results database and multi-center cases. *J Cancer Res Clin Oncol.* 2023 Nov;149(15):13665-13676. Epub 2023 Jul 31.
377. Koroukian SM, Douglas SL, Vu L, Fein HL, Gairola R, Warner DF, Schiltz NK, Cullen J, Owusu C, Sajatovic M, Rose J. Aggressive end-of-life care across gradients of cognitive impairment in nursing home patients with metastatic cancer. *J Am Geriatr Soc.* 2023 Nov;71(11):3546-3553. Epub 2023 Jul 29.
378. Jiang Q, Zhan G, Jiang W, Xu Y, Zheng G, Jiang C, Lin D, Wang K, Zhu H. Prognostic model and treatment choices for patients with primary intracranial central nervous system lymphoma: A population-based study. *Clin Neurol Neurosurg.* 2023 Oct;233:107912. Epub 2023 Jul 26.
379. Charalel RA, Mushlin AI, Zheng X, Mao J, Carlos RC, Brown RS Jr, Fortune BE, Talenfeld AD, Madoff DC, Ibrahim S, Johnson MS, Sedrakyan A. Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort. *J Vasc Interv Radiol.* 2023 Nov;34(11):1997-2005.e3. Epub 2023 Jul 17.
380. Killeen TF, Shanley R, Ramesh V, Giubellino A. Malignant Melanoma in a Retrospective Cohort of Immunocompromised Patients: A Statistical and Pathologic Analysis. *Cancers (Basel).* 2023 Jul 13;15. (14).
381. Shallis RM, Wang R, Zeidan AM, Huntington SF, Neparidze N, Stempel JM, Mendez LM, Di M, Ma X, Podoltsev NA. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. *Blood Adv.* 2023 Jul 11;7(13):3213-3224.
382. Brunner AM, Huggar D, Copher R, Zhou ZY, Zichlin ML, Anderson A, Downes N, McBride A. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database. *Leuk Res.* 2023 Sep;132:107353. Epub 2023 Jul 10.
383. Khired ZA, Hussein MH, Jishu JA, Toreih AA, Shaalan AAM, Ismail MM, Fawzy MS, Toraih EA. Osseous Metastases in Thyroid Cancer: Unveiling Risk Factors, Disease Outcomes, and Treatment Impact. *Cancers (Basel).* 2023 Jul 10;15. (14).
384. Ni X, Luu M, Ma W, Zhang T, Wei Y, Freedland SJ, Ye D, Daskivich TJ, Zhu Y. Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer. *J Natl Compr Canc Netw.* 2023 Jul;21(7):733-741.e3.

385. Wang CY, Shao C, McDonald AC, Amonkar MM, Zhou W, Bortnichak EA, Liu X. Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer. *JCO Clin Cancer Inform*. 2023 Jul;7:e2200184.
386. West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer. *J Manag Care Spec Pharm*. 2023 Jul;29(7):749-757.
387. Allaire BT, Zabala D, Lines LM, Williams C, Halpern M, Mollica M. Associations between healthcare costs and care experiences among older adults with and without cancer. *J Geriatr Oncol*. 2023 Sep;14(7):101561. Epub 2023 Jun 29.
388. Rawicz-Pruszyński K, Woldesenbet S, Endo Y, Munir MM, Katayama E, Waqar U, Khan MMM, Khalil M, Rueda BO, Resende V, Dillhoff M, Cloyd J, Ejaz A, Pawlik TM. Persistent poverty impacts access to minimally invasive surgery among patients with hepatopancreatobiliary cancer. *J Surg Oncol*. 2023 Oct;128(5):823-830. Epub 2023 Jun 28.
389. Zhai T, Ma J, Liu Y, Li H, Peng Y, Guo W, Jia J, Wu X, Jiang H, Tian J, Wang D. The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: A population-based study. *Cancer Med*. 2023 Aug;12(16):16697-16706. Epub 2023 Jun 27.
390. Li Z, Pang M, Liang X, Zhang Y, Zhang W, He W, Sheng L, An Y. Risk factors of early mortality in patients with small cell lung cancer: a retrospective study in the SEER database. *J Cancer Res Clin Oncol*. 2023 Oct;149(13):11193-11205. Epub 2023 Jun 24.
391. Anderson C, Peery AF, Bae-Jump VL, Brewster WR, Lund JL, Olshan AF, Nichols HB. Gastrointestinal outcomes among older women with endometrial cancer. *Gynecol Oncol*. 2023 Aug;175:114-120. Epub 2023 Jun 22.
392. Joyce DD, Qin X, Sharma V, Boorjian SA, Barocas DA, Dusetzina SB, Moses KA. The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer. *J Urol*. 2023 Sep;210(3):447-453. Epub 2023 Jun 21.
393. Yumeen S, Mirza FN, Mirza HN, Zogg CK, Leventhal JS, Cohen JM. Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database. *J Am Acad Dermatol*. 2023 Oct;89(4):843-846. Epub 2023 Jun 19.
394. Zheng D, Thomas J 3rd. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer. *Breast Cancer Res Treat*. 2023 Aug;201(1):89-104. Epub 2023 Jun 16.
395. Gordon MJ, Duan Z, Zhao H, Nastoupil L, Ferrajoli A, Danilov AV, Giordano SH. A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. *Blood Adv*. 2023 Jun 13;7(11):2632-2642.
396. Lee DH, Jin Q, Shi N, Wang F, Bever AM, Li J, Liang L, Hu FB, Song M, Zeleznik OA, Zhang X, Joshi A, Wu K, Jeon JY, Meyerhardt JA, Chan AT, Eliassen AH, Clish CB, Clinton SK, Giovannucci EL, Tabung FK. Dietary Inflammatory and Insulinemic Potentials, Plasma Metabolome and Risk of Colorectal Cancer. *Metabolites*. 2023 Jun 12;13. (6).
397. Liu H, Shui IM, Keum N, Shen X, Wu K, Clinton SK, Cao Y, Song M, Zhang X, Platz EA, Giovannucci EL. Plasma total cholesterol concentration and risk of higher-grade prostate cancer: A nested case-control study and a dose-response meta-analysis. *Int J Cancer*. 2023 Oct 1;153(7):1337-1346. Epub 2023 Jun 12.
398. Farvid MS, Spence ND, Rosner BA, Barnett JB, Holmes MD. Associations of low-carbohydrate diets with breast cancer survival. *Cancer*. 2023 Sep 1;129(17):2694-2704. Epub 2023 Jun 10.

399. Bikomeye JC, Zhou Y, McGinley EL, Canales B, Yen TWF, Tarima S, Ponce SB, Beyer KMM. Historical redlining and breast cancer treatment and survival among older women in the United States. *J Natl Cancer Inst.* 2023 Jun 8;115(6):652-661.
400. Mburu W, Devesa SS, Check D, Shiels MS, Mbulaiteye SM. Incidence of Burkitt lymphoma in the United States during 2000 to 2019. *Int J Cancer.* 2023 Sep 15;153(6):1182-1191. Epub 2023 Jun 6.
401. Zambrano IA, Hwang S, Basak R, Spratte BN, Filson CP, Jacobs BL, Tan HJ. Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance. *Urol Oncol.* 2023 Sep;41(9):388.e1-388.e8. Epub 2023 Jun 5.
402. Yang S, Chang W, Zhang B, Shang P. What factors are associated with the prognosis of primary testicular diffuse large B-cell lymphoma? A study based on the SEER database. *J Cancer Res Clin Oncol.* 2023 Sep;149(12):10269-10278. Epub 2023 Jun 4.
403. Mariotto AB, Thompson TD, **Johnson C**, Wu XC, Pollack LA. Breast and colorectal cancer recurrence-free survival estimates in the US: Modeling versus active data collection. *Cancer Epidemiol.* Aug 2023;85:102370.
404. Bailey CN, Martin BJ, Petkov VI, Schussler NC, Stevens JL, Bentler S, Cress RD, Doherty JA, Durbin EB, Gomez SL, Gonsalves L, Hernandez BY, Liu L, **Morawski BM**, Schymura MJ, Schwartz SM, Ward KC, Wiggins C, Wu XC, Goldberg MS, Siegel JJ, Cook RW, Covington KR, Kurley SJ. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. *JCO Precis Oncol.* 2023 Jun;7:e2300044.
405. Zaorsky NG, Proudfoot JA, Jia AY, Zuhour R, Vince Jr. R, Liu Y, Zhao X, Hu J, Schussler NC, Stevens JL, Bentler S, Cress RD, Doherty JA, Durbin EB, Gershman S, Cheng I, Gonsalves L, Hernandez BY, Liu L, **Morawski BM**,...Spratt DE. Use of the Decipher genomic classifier among men with prostate cancer in the United States. *JNCI Cancer Spectr.* 2023. 7(5).
406. Ramaswamy A, Zhang TR, Hu JC. US News & World Report Hospital Ratings on Radical Prostatectomy. *JAMA Surg.* 2023 Jun 1;158(6):570-571.
407. Pinsky PF, Osarogiagbon R. Diagnostic follow-up of indeterminate pulmonary nodules in the Medicare population. *Cancer.* 2023 Sep 15;129(18):2808-2816. Epub 2023 May 19.
408. Kim H, Yuan C, Nguyen LH, Ng K, Giovannucci EL. Prediagnostic Vitamin D Status and Colorectal Cancer Survival by Vitamin D Binding Protein Isoforms in US Cohorts. *J Clin Endocrinol Metab.* 2023 May 17;108(6):e223-e229.
409. Shi J, Kraft P, Rosner BA, Benavente Y, Black A, Brinton LA, Chen C, Clarke MA, Cook LS, Costas L, Dal Maso L, Freudenheim JL, Frias-Gomez J, Friedenreich CM, Garcia-Closas M, Goodman MT, Johnson L, La Vecchia C, Levi F, Lissowska J, Lu L, McCann SE, Moysich KB, Negri E, O'Connell K, Parazzini F, Petruzella S, Polesel J, Ponte J, Rebbeck TR, Reynolds P, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Shu XO, Spurdle AB, Trabert B, Webb PM, Wentzensen N, Wilkens LR, Xu WH, Yang HP, Yu H, Du M, De Vivo I. Risk prediction models for endometrial cancer: development and validation in an international consortium. *J Natl Cancer Inst.* 2023 May 8;115(5):552-559.
410. Halpern MT, McNeel TS, Kozono D, Mollica MA. Association of Patient Experience of Care and Radiation Therapy Initiation Among Women With Early-Stage Breast Cancer. *Pract Radiat Oncol.* 2023 Sep-Oct;13(5):434-443. Epub 2023 May 6.
411. Spratte BN, Tan HJ, Zambrano IA, Basak RS, Filson CP, Jacobs BL, Hwang S. Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach? *Urol Oncol.* 2023 Jul;41(7):323.e17-323.e25. Epub 2023 May 5.
412. Huang J, Chan SC, Lok V, Zhang L, Lin X, Lucero-Prisno DE, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS, NCD Global Health Research Group, Association of Pacific Rim Universities (APRU). Disease burden, risk factors, and trends of primary central nervous

system (CNS) cancer: A global study of registries data. *Neuro Oncol.* 2023 May 4;25(5):995-1005.

413. Swami U, Aggarwal H, Zhou M, Jiang S, Kim J, Li W, Laliberté F, Emond B, Agarwal N. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data. *Clin Genitourin Cancer.* 2023 Oct;21(5):517-529. Epub 2023 May 3.
414. Finn CB, Sharpe JE, Tong JK, Kaufman EJ, Wachtel H, Aarons CB, Weissman GE, Kelz RR. Development of a Machine Learning Model to Identify Colorectal Cancer Stage in Medicare Claims. *JCO Clin Cancer Inform.* 2023 May;7:e2300003.
415. Upshaw JN, Nelson J, Rodday AM, Kumar AJ, Klein AK, Konstam MA, Wong JB, Jaffe IZ, Ky B, Friedberg JW, Maurer M, Kent DM, Parsons SK. Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma. *JAMA Cardiol.* 2023 May 1;8(5):453-461.
416. Kim J, Khil J, Kim H, Keum N, Zhang X, Giovannucci E. Plant-based dietary patterns and the risk of digestive system cancers in 3 large prospective cohort studies. *Eur J Epidemiol.* 2023 Jun;38(6):617-627. Epub 2023 Apr 26.
417. Dibble KE, Deng Z, Connor AE. Differences in survivorship care experiences among older breast cancer survivors by clinical cancer characteristics, race/ethnicity, and socioeconomic factors: A SEER-CAHPS study. *Breast Cancer Res Treat.* 2023 Jun;199(3):565-582. Epub 2023 Apr 24.
418. Lee S, Bennett AV, Zhou X, Betof Warner A, Trogdon JG, Kent EE, Lund JL. Real-world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy. *Pharmacoepidemiol Drug Saf.* 2023 Sep;32(9):988-1000. Epub 2023 Apr 24.
419. Cao Y, Liu W, Gu D. A nomogram for predicting overall survival of patients with squamous cell carcinoma of the floor of the mouth: a population-based study. *Eur Arch Otorhinolaryngol.* 2023 Aug;280(8):3867-3875. Epub 2023 Apr 18.
420. Shi M, Zong X, Hur J, Birmann BM, Martinez-Maza O, Epeldegui M, Chan AT, Giovannucci EL, Cao Y. Circulating markers of microbial translocation and host response to bacteria with risk of colorectal cancer: a prospective, nested case-control study in men. *EBioMedicine.* 2023 May;91:104566. Epub 2023 Apr 17.
421. Katayama ES, Moazzam Z, Woldesenbet S, Lima HA, Endo Y, Azap L, Yang J, Dillhoff M, Ejaz A, Cloyd J, Pawlik TM. Suicidal Ideation Among Patients with Gastrointestinal Cancer. *Ann Surg Oncol.* 2023 Jul;30(7):3929-3938. Epub 2023 Apr 16.
422. Oh J, Abboud Y, Burch M, Gong J, Waters K, Ghaith J, Jiang Y, Park K, Liu Q, Watson R, Lo SK, Gaddam S. Rising Incidence of Non-Cardia Gastric Cancer among Young Women in the United States, 2000-2018: A Time-Trend Analysis Using the USCS Database. *Cancers (Basel).* 2023 Apr 13;15. (8).
423. Neibart SS, Malhotra J, Roy JA, Strom BL, Jabbour SK. Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy. *J Thorac Dis.* 2023 May 30;15(5):2458-2468. Epub 2023 Apr 12.
424. Fang L, Tuohuti A, Shi L, Chen X. Comparison of prognostic and treatment between T1a and T1b glottic cancer: a propensity score-matched SEER database analysis. *Eur Arch Otorhinolaryngol.* 2023 Jul;280(7):3313-3322. Epub 2023 Apr 11.
425. Sun Y, Li Z, Tian Y, Gao C, Liang B, Cao S, Liu X, Liu X, Meng C, Xu J, Yang H, Zhou Y. Development and validation of nomograms for predicting overall survival and cancer-specific survival in elderly patients with locally advanced gastric cancer: a population-based study. *BMC Gastroenterol.* 2023 Apr 11;23(1):117.

426. Ericsson CI, Pacheco LS, Romanos-Nanclares A, Ecsedy E, Giovannucci EL, Eliassen AH, Mucci LA, Fu BC. Prospective Study of Avocado Consumption and Cancer Risk in U.S. Men and Women. *Cancer Prev Res (Phila)*. 2023 Apr 3;16(4):211-218.
427. Chang CY, Park H, Hincapie-Castillo JM, Heldermon CD, Diaby V, Yang S, Wilson DL, Lo-Ciganic WH. Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression. *J Manag Care Spec Pharm*. 2023 Apr;29(4):431-445.
428. Shi S, Wang K, Zhong R, Cassidy A, Rimm EB, Nimptsch K, Wu K, Chan AT, Giovannucci EL, Ogino S, Ng K, Meyerhardt JA, Song M. Flavonoid intake and survival after diagnosis of colorectal cancer: a prospective study in 2 US cohorts. *Am J Clin Nutr*. 2023 Jun;117(6):1121-1129. Epub 2023 Apr 1.
429. Dennis LK, Brown HE, Arrington AK. Comparison of Prognostic Factors for Merkel Cell Carcinoma, Mucosal Melanoma and Cutaneous Malignant Melanoma: Insights into Their Etiologies. *Curr Oncol*. 2023 Mar 31;30(4):3974-3988.
430. Benjamin WJ, Yalamanchi P, Taylor JMG, Lenze N, Worden FP, Chinn SB, Chen MM. Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs. *Head Neck*. 2023 Jun;45(6):1468-1475. Epub 2023 Mar 28.
431. Jayadevappa R, Guzzo T, Vapiwala N, Malkowicz SB, Gallo JJ, Chhatre S. Continuity of care and advanced prostate cancer. *Cancer Med*. 2023 May;12(10):11795-11805. Epub 2023 Mar 23.
432. Farland LV, Wang S, Rich-Edwards JW, Gaskins AJ, Chavarro JE, Wang YX, Tamimi RM, Missmer SA. History of infertility and risk of breast cancer: a prospective cohort study. *Breast Cancer Res Treat*. 2023 May;199(1):185-193. Epub 2023 Mar 16.
433. Girardi F, Di Carlo V, Stiller C, Gatta G, Woods RR, Visser O, Lacour B, Tucker TC, Coleman MP, Allemani C, CONCORD Working Group. Global survival trends for brain tumors, by histology: Analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3). *Neuro Oncol*. 2023 Mar 14;25(3):593-606.
434. Wang R, Shallis RM, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. *Blood Adv*. 2023 Mar 14;7(5):734-743.
435. Sun H, Wu S, Li S, Jiang X. Which model is better in predicting the survival of laryngeal squamous cell carcinoma?: Comparison of the random survival forest based on machine learning algorithms to Cox regression: analyses based on SEER database. *Medicine (Baltimore)*. 2023 Mar 10;102(10):e33144.
436. Corey L, Seaton R, Ruterbusch JJ, Bretschneider CE, Vezina A, Do T, Hobson D, Winer I. Concurrent Surgery for Locoregional Gynecologic Cancers and Pelvic Floor Disorders in a Population of Patients With Medicare Insurance. *Obstet Gynecol*. 2023 Apr 1;141(4):629-641. Epub 2023 Mar 9.
437. Hu X, Lipscomb J, Jiang C, Graetz I. Vertical integration of oncologists and cancer outcomes and costs in metastatic castration-resistant prostate cancer. *J Natl Cancer Inst*. 2023 Mar 9;115(3):268-278.
438. Romanos-Nanclares A, Tabung FK, Sinnott JA, Trabert B, De Vivo I, Playdon MC, Eliassen AH. Inflammatory and insulinemic dietary patterns and risk of endometrial cancer among US women. *J Natl Cancer Inst*. 2023 Mar 9;115(3):311-321.
439. Wang Y, Wang S, Qu Y, Yang Y. Clinicopathological characteristics, treatment and prognosis of oral adenocarcinoma: a population-based study. *Eur Arch Otorhinolaryngol*. 2023 Jul;280(7):3365-3374. Epub 2023 Mar 9.
440. Hathaway CA, Rice MS, Collins LC, Chen D, Frank DA, Walker S, Clevenger CV, Tamimi RM, Tworoger SS, Hankinson SE. Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers. *Breast Cancer Res*. 2023 Mar 7;25(1):24.

441. Nash SH, Wahlen MM, Meisner ALW, **Morawski BM**. Choice of Survival Metric and Its Impacts on Cancer Survival Estimates for American Indian and Alaska Native People. *Cancer Epidemiol Biomarkers Prev*. 2023 Mar 6;32(3):398-405.
442. Fulop DJ, Zylberberg HM, Wu YL, Aronson A, Labiner AJ, Wisnivesky J, Cohen DJ, Sigel KM, Lucas AL. Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. *JAMA Netw Open*. 2023 Mar 1;6(3):e234254.
443. Tappero S, Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Garcia CC, Piccinelli M, Tian Z, Parodi S, Montorsi F, Chun FKH, Graefen M, Antonelli A, Saad F, Shariat SF, De Cobelli O, Suardi NR, Borghesi M, Terrone C, Karakiewicz PI. The effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy. *Can Urol Assoc J*. 2023 Mar;17(3):E50-E56.
444. Tan Z, Chen Z, Yao G, Mumin MA, Wang Y, Zhu J, Xu Q, Chen W, Liang H, Wang Z, Deng Q, Luo J, Wei J, Cao J. Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving overall survival and cancer-specific survival among muscle invasive bladder cancer patients who undergo radical cystectomy: a retrospective cohort study based on SEER database. *Transl Androl Urol*. 2023 Feb 28;12(2):330-346. Epub 2023 Feb 27.
445. Liu Y, Zhao YC, Lu Y, Goodarz D, Gershman B. The role of smoking in explaining racial/ethnic disparities in bladder cancer incidence in the United States. *Urol Oncol*. 2023 Sep;41(9):389.e1-389.e6. Epub 2023 Feb 26.
446. Zhang H, Barner JC, Moczygemba LR, Rascati KL, Park C, Kodali D. Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis. *Breast Cancer*. 2023 May;30(3):489-496. Epub 2023 Feb 26.
447. Lee JM, Wang R, Johnson A, Ogale S, Kent M, Lee JS. Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC. *JTO Clin Res Rep*. 2023 Feb 25;4(4):100487. doi: 10.1016/j.jtocrr.2023.100487. eCollection 2023 Apr.
448. Wang S, Gaskins AJ, Farland LV, Zhang D, Birmann BM, Rich-Edwards JW, Wang YX, Tamimi RM, Missmer SA, Chavarro JE. A prospective cohort study of infertility and cancer incidence. *Fertil Steril*. 2023 Jul;120(1):134-142. Epub 2023 Feb 25.
449. Dong W, Okamoto T, Ji X, Xiang J, Zhang D, Zhang P, Zhang H. Conditional Survival Rate Estimates for Anaplastic Thyroid Cancer Beyond the First Year: An Analysis of SEER Data (2004-2019). *Thyroid*. 2023 Apr;33(4):523-526. Epub 2023 Feb 24.
450. Parsons SK, Keegan THM, Kirchhoff AC, Parsons HM, Yabroff KR, Davies SJ. Cost of Cancer in Adolescents and Young Adults in the United States: Results of the 2021 Report by Deloitte Access Economics, Commissioned by Teen Cancer America. *J Clin Oncol*. 2023 Jun 10;41(17):3260-3268. Epub 2023 Feb 24.
451. Fang S, Wang X, Wu X, Li H. Therapeutic response analysis for patients with adenosquamous carcinoma of the gallbladder: data analysis based on the Surveillance, Epidemiology, and End Results (SEER) database. *J Gastrointest Oncol*. 2023 Feb 28;14(1):405-419. Epub 2023 Feb 21.
452. Lee AW, Sou A, Patel M, Guzman S, Liu L. Early onset of nasopharyngeal cancer in Asian/Pacific Islander Americans revealed by age-specific analysis. *Ann Epidemiol*. 2023 Apr;80:25-29. Epub 2023 Feb 20.
453. Birch K, Chung S, Zion SR, MacEwan JP, Malecki MJ. Incremental Health Care Costs of Anxiety and Depression Among Medicare Beneficiaries With Cancer. *JCO Oncol Pract*. 2023 May;19(5):e660-e671. Epub 2023 Feb 17.
454. Zhou N, Niu J, Nelson D, Feldman HA, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Swisher SG, Walsh GL, Giordano SH, Rajaram R. Surgical Approach and Persistent Opioid Use in Medicare Patients Undergoing Lung Cancer Resection. *Ann Thorac Surg*. 2023 Nov;116(5):1020-1027. Epub 2023 Feb 16.

455. Dhamane AD, Shah S, Noxon V, Bruette R, Ferri M, Liu X, Jiang J, Luo X. Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer. *Thromb Res.* 2023 Apr;224:52-59. Epub 2023 Feb 15.
456. Haas NB, Song Y, Willemann Rogerio J, Zhang S, Carley C, Zhu J, Bhattacharya R, Signorovitch J, Sundaram M. Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data. *Int J Urol.* 2023 Mar;30(3):272-279. Epub 2023 Feb 14.
457. Luo J, Hendryx M, Dong Y. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival. *Br J Cancer.* 2023 Apr;128(8):1541-1547. Epub 2023 Feb 10.
458. Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. *Cancer.* 2023 Apr 1;129(7):1051-1063. Epub 2023 Feb 9.
459. Hong YD, Mullins CD, Onukwugha E, Yared JA, Zheng Z, Slejko JF. Association of individual low-income status and area deprivation with mortality in multiple myeloma. *J Geriatr Oncol.* 2023 Mar;14(2):101415. Epub 2023 Feb 9.
460. Park C, Heo JH, Mehta S, Han S, Spencer JC. Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer. *Clin Drug Investig.* 2023 Mar;43(3):167-176. Epub 2023 Feb 6.
461. Dong W, Kim U, Rose J, Hoehn RS, Kucmanic M, Eom K, Li S, Berger NA, Koroukian SM. Geographic Variation and Risk Factor Association of Early Versus Late Onset Colorectal Cancer. *Cancers (Basel).* 2023 Feb 4;15. (4).
462. Koroukian SM, Douglas SL, Vu L, Fein HL, Gairola R, Warner DF, Schiltz NK, Cullen J, Owusu C, Sajatovic M, Rose J. Incidence of Aggressive End-of-Life Care Among Older Adults With Metastatic Cancer Living in Nursing Homes and Community Settings. *JAMA Netw Open.* 2023 Feb 1;6(2):e230394.
463. Riaz IB, Islam M, Ikram W, Naqvi SAA, Maqsood H, Saleem Y, Riaz A, Ravi P, Wang Z, Hussain SA, Warner JL, Odedina FT, Duma N, Singh P, Kehl KL, Kamran SC, Murad MH, Landman A, Van Allen E, Bryce AH. Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. *JAMA Oncol.* 2023 Feb 1;9(2):180-187.
464. Samaan JS, Abboud Y, Oh J, Jiang Y, Watson R, Park K, Liu Q, Atkins K, Hendifar A, Gong J, Osipov A, Li D, Nissen NN, Pandol SJ, Lo SK, Gaddam S. Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000-2018. *Cancers (Basel).* 2023 Jan 31;15. (3).
465. Abdelrahman AM, Yin J, Alva-Ruiz R, Yonkus JA, Leiting JL, Lynch IT, Fogliati A, Campbell NA, Carlson DM, Roberts LR, Gores GJ, Smoot RL, Graham RP, Halfdanarson TR, Truty MJ. Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States. *Cancers (Basel).* 2023 Jan 30;15. (3).
466. Zhang GT, Liu Q, Zuo FX, Liu HJ, Wang SQ, Yuan Q, Liu AS, Hu K, Meng XL, Wang WJ, Qian HP, Wan JH, Cai HQ. Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma. *BMC Cancer.* 2023 Jan 30;23(1):104.
467. Ullah A, Saeed O, Karki NR, Goodbee M, Yasinza AQK, Waheed A, Heneidi S, Thomas A, Karim NA, Johnson J, Del Rivero J, Khan J. Clinicopathological and Treatment Patterns of Combined Small-Cell Lung Carcinoma with Future Insight to Treatment: A Population-Based Study. *J Clin Med.* 2023 Jan 28;12. (3).

468. Haghayegh S, Liu Y, Zhang Y, Strohmaier S, Papantoniou K, Markt S, Giovannucci E, Schernhammer E. Rotating Night Shift Work and Bladder Cancer Risk in Women: Results of Two Prospective Cohort Studies. *Int J Environ Res Public Health*. 2023 Jan 26;20. (3).
469. Schonberg MA, Wolfson EA, Eliassen AH, Bertrand KA, Shvetsov YB, Rosner BA, Palmer JR, Ngo LH. A model for predicting both breast cancer risk and non-breast cancer death among women > 55 years old. *Breast Cancer Res*. 2023 Jan 24;25(1):8.
470. Zhao Z, Gao Y, Tan F, Xue Q, Gao S, He J. Specific organ metastases and prognosis in lung adenocarcinoma. *Thorac Cancer*. 2023 Mar;14(8):736-745. Epub 2023 Jan 24.
471. Hathaway CA, Wang T, Townsend MK, Vinci C, Jake-Schoffman DE, Saeed-Vafa D, Moran Segura C, Nguyen JV, Conejo-Garcia JR, Fridley BL, Tworoger SS. Lifetime Exposure to Cigarette Smoke and Risk of Ovarian Cancer by T-cell Tumor Immune Infiltration. *Cancer Epidemiol Biomarkers Prev*. 2023 Jan 9;32(1):66-73.
472. Goyal RK, Holmes HM, Chen H, Abughosh S, Candrilli SD, Johnson ML. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2-metastatic breast cancer in the United States. *Breast Cancer Res Treat*. 2023 Feb;198(1):159-166. Epub 2023 Jan 7.
473. Fortner RT, Brantley KD, Tworoger SS, Tamimi RM, Rosner B, Farvid MS, Holmes MD, Willett WC, Eliassen AH. Physical activity and breast cancer survival: results from the Nurses' Health Studies. *JNCI Cancer Spectr*. 2023 Jan 3;7. (1).
474. Chen Q, Qu L, He Y, Deng Y, Zhou Q, Yi W. Comparative effectiveness of nipple-sparing mastectomy and breast-conserving surgery on long-term prognosis in breast cancer. *Front Endocrinol (Lausanne)*. 2023 Nov 20;14:1222651. doi: 10.3389/fendo.2023.1222651. eCollection 2023.
475. Chen R, Lu Y, Horie S, Vogel M, Zhang R, Zheng P, Wei Y. Cancer-directed surgery brings survival benefits for patients with advanced prostate cancer: a population-based propensity-score matching study. *J Cancer*. 2023 Jan 1;14(2):231-238. doi: 10.7150/jca.80232. eCollection 2023.
476. Du XL, Song L. A Large Retrospective Cohort Study on the Risk of Alzheimer's Disease and Related Dementias in Association with Vascular Diseases and Cancer Therapy in Men with Prostate Cancer. *J Prev Alzheimers Dis*. 2023;10(2):193-206.
477. Gerber TS, Strobl S, Marx A, Roth W, Porubsky S. Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999-2019. *Front Oncol*. 2024 Jan 9;13:1308989. doi: 10.3389/fonc.2023.1308989. eCollection 2023.
478. Hofer BM, Weir HK, Eckstrand A, Musonda K, Sherman R. The Burden of Rare Cancers in North America. *J Registry Manag*. 2023 Winter;50(4):123-137.
479. Jia G, Lei P, Zhang Y, Zheng Z, Fang J, Yang X, Wei H, Chen T. New staging systems for left-sided colon cancer based on the number of retrieved and metastatic lymph nodes provide a more accurate prognosis. *Pathol Oncol Res*. 2023 Feb 24;29:1610874. doi: 10.3389/pore.2023.1610874. eCollection 2023.
480. Li S, Chen C, Zhu H, Lin Q, Yu Z. Risk Evaluation of Bone Metastases and a Simple Tool for Detecting Bone Metastases in Prostate Cancer: A Population-Based Study. *Comput Math Methods Med*. 2023 Feb 14;2023:9161763. doi: 10.1155/2023/9161763. eCollection 2023.
481. Mattis A, Beydoun H, Dobryднева Y, Ganjoo R. Investigating the Efficacy of HPV Vaccines in Preventing Cervical Cancer from 2006 to 2018 in the US: A SEER Data Set Analysis. *Rev Recent Clin Trials*. 2023;18(3):214-222.
482. Meng XY, Wang QL, Shi MJ, Zhang HY. Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility. *Bladder Cancer*. 2023 Sep 25;9(3):211-216. doi: 10.3233/BLC-230010. eCollection 2023.
483. Shaikh NF, Shen C, LeMasters T, Dwibedi N, Ladani A, Sambamoorthi U. Prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Incidence of Depression Among Older

- Cancer Survivors With Osteoarthritis: A Machine Learning Analysis. *Cancer Inform.* 2023 Apr 18;22:11769351231165161. doi: 10.1177/11769351231165161. eCollection 2023.
484. Wang H, Yang D, Lv Y, Lin J, Wang H. Operative versus Nonoperative Treatment in Patients with Advanced Non-Small-Cell Lung Cancer: Recommended for Surgery. *Can Respir J.* 2023 Jan 12;2023:4119541. doi: 10.1155/2023/4119541. eCollection 2023.
 485. Wang J, Li X, Niu D, Huang J, Ye E, Zhao Y, Yue S, Hou X, Wu J. Mortality patterns of patients with tonsillar squamous cell carcinoma: a population-based study. *Front Endocrinol (Lausanne).* 2023 Dec 7;14:1158593. doi: 10.3389/fendo.2023.1158593. eCollection 2023.
 486. West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A. Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data. *Clin Lung Cancer.* 2023 May;24(3):260-268. Epub 2022 Dec 25.
 487. Alvarez A, Bernal AM, Anampa J. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. *Breast Cancer Res Treat.* 2023 Feb;198(1):75-88. Epub 2022 Dec 23.
 488. Schafer EJ, Jemal A, Wiese D, Sung H, Kratzer TB, Islami F, Dahut WL, Knudsen KE. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. *Eur Urol.* 2023 Jul;84(1):117-126. Epub 2022 Dec 21.
 489. Olsen TA, Filson CP, Richards TB, Ekwueme DU, Howard DH. The Cost of Metastatic Prostate Cancer in the United States. *Urol Pract.* 2023 Jan;10(1):41-47. Epub 2022 Dec 19.
 490. Pinsky P, Miller E, Faris N, Osarogiagbon R. Pulmonary Nodules, Lung Cancer Screening, and Lung Cancer in the Medicare Population. *Chest.* 2023 May;163(5):1304-1313. Epub 2022 Dec 15.
 491. Yu W, Lu Y, Shou H, Xu H, Shi L, Geng X, Song T. A 5-year survival status prognosis of nonmetastatic cervical cancer patients through machine learning algorithms. *Cancer Med.* 2023 Mar;12(6):6867-6876. Epub 2022 Dec 8.
 492. Doose M, Verhoeven D, Sanchez JI, McGee-Avila JK, Chollette V, Weaver SJ. Clinical Multiteam System Composition and Complexity Among Newly Diagnosed Early-Stage Breast, Colorectal, and Lung Cancer Patients With Multiple Chronic Conditions: A SEER-Medicare Analysis. *JCO Oncol Pract.* 2023 Jan;19(1):e33-e42. Epub 2022 Dec 6.
 493. Park J, Kent EE, Lund JL, Anderson C, Olshan AF, Brewster WR, Nichols HB. Adjuvant radiation therapy and health-related quality of life among older women with early-stage endometrial cancer: an analysis using the SEER-MHOS linkage. *Cancer Causes Control.* 2023 Mar;34(3):223-231. Epub 2022 Dec 2.
 494. Cohen CM, Wentzensen N, Castle PE, Schiffman M, Zuna R, Arend RC, Clarke MA. Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype. *J Clin Oncol.* 2023 Feb 10;41(5):1059-1068. Epub 2022 Dec 1.
 495. Zhang Y, Stopsack KH, Wu K, Song M, Mucci LA, Giovannucci E. Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer. *J Urol.* 2023 Mar;209(3):549-556. Epub 2022 Dec 1.
 496. Weng X, Shen C, Vasekar M, Boltz M, Joshi M, Van Scoy LJ, Wang L. Alzheimer's disease and related dementias is a risk factor for lower utilization of breast cancer screening and unstaged cancer diagnosis: Observational study from SEER-Medicare 2004-2016 data. *J Geriatr Oncol.* 2023 Apr;14(3):101407. Epub 2022 Nov 26.
 497. Daftary K, Fiessinger L, Gerami P, Nardone B, Liszewski W. Differences in the demographics, incidence, and survival of palmar and plantar acral melanoma: a population-based study. *Arch Dermatol Res.* 2023 May;315(4):957-961. Epub 2022 Nov 23.
 498. Nikšić M, Minicozzi P, Weir HK, Zimmerman H, Schymura MJ, Rees JR, Coleman MP, Allemani C, US CONCORD Working Group. Pancreatic cancer survival trends in the US

- from 2001 to 2014: a CONCORD-3 study. *Cancer Commun (Lond)*. 2023 Jan;43(1):87-99. Epub 2022 Nov 9.
499. Plichta JK, Rushing CN, Lewis HC, Rooney MM, Blazer DG, Thomas SM, Hwang ES, Greenup RA. Implications of missing data on reported breast cancer mortality. *Breast Cancer Res Treat*. 2023 Jan;197(1):177-187. Epub 2022 Nov 5.
 500. Desai AD, Chinta S, Yeh C, Shah VP, Shah R, Paskhover B, Schwartz RA. An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability. *Arch Dermatol Res*. 2023 May;315(4):799-806. Epub 2022 Nov 1.
 501. Finn CB, Wirtalla C, Mascuilli T, Krumeich LN, Wachtel H, Fraker D, Kelz RR. Simulated data-driven hospital selection for surgical treatment of well-differentiated thyroid cancer in older adults. *Surgery*. 2023 Jan;173(1):207-214. Epub 2022 Oct 22.
 502. Tappero S, Piccinelli M, Barletta F, Panunzio A, Cano Garcia C, Incesu RB, Tian Z, Parodi S, Dell'Oglio P, De Cobelli O, Briganti A, Antonelli A, Chun FKH, Graefen M, Saad F, Shariat SF, Suardi NR, Borghesi M, Terrone C, Karakiewicz PI. Effect of inguinal lymph node dissection in lymph node negative patients with squamous cell carcinoma of the penis. *World J Urol*. 2023 Jan;41(1):119-125. Epub 2022 Oct 14.
 503. Elshanbary AA, Zilai AH, Ishqair A, Matar SG, Nourelden AZ, Hafez AH, Altyar AE, Albadrani GM, Zaazouee MS. Demographic and treatment risk factors of cancer-specific mortality among children and adolescent leukemia patients: a population-based study. *Environ Sci Pollut Res Int*. 2023 Feb;30(7):19182-19193. Epub 2022 Oct 12.
 504. Chen H, Wu J, Guo W, Yang L, Lu L, Lin Y, Wang X, Zhang Y, Chen X. Clinical models to predict lymph nodes metastasis and distant metastasis in newly diagnosed early esophageal cancer patients: A population-based study. *Cancer Med*. 2023 Mar;12(5):5275-5292. Epub 2022 Oct 7.
 505. Alam MU, Kumar J, Norez D, Woolfe J, Tanneru K, Jazayeri SB, Bazargani S, Thomas D, Gautam S, Costa J, Bandyk M, Ganapathi HP, Koochekpour S, Balaji KC. Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at ≤ 55 years of age: a 25-year follow-up of $> 60,000$ men. *Int Urol Nephrol*. 2023 Feb;55(2):295-300. Epub 2022 Sep 29.
 506. Park J, Lund JL, Kent EE, Anderson C, Brewster WR, Olshan AF, Nichols HB. Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer. *J Geriatr Oncol*. 2023 Jan;14(1):101371. Epub 2022 Sep 8.
 507. Panunzio A, Sorce G, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Tian Z, Tafuri A, De Cobelli O, Chun FKH, Tilki D, Terrone C, Briganti A, Kapoor A, Saad F, Shariat SF, Cerruto MA, Antonelli A, Karakiewicz PI. Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2023 Apr;21(2):295-300. Epub 2022 Aug 26.
 508. Tanaka T, Lynch CF, Yu KJ, **Morawski BM**, Hsieh MC, Alverson G, Austin AA, Zeng Y, Engels EA. Pancreatic cancer among solid organ transplant recipients in the United States. *J Cancer Res Clin Oncol*. 2023 Jul;149(7):3325-3333. Epub 2022 Aug 6. (*Also listed in "Publications using CDRI data, Dec 2019–Dec 2022" as Epub.*)
 509. Wenzel M, Collà Ruvo C, Würnschimmel C, Nocera L, Hoeh B, Tian Z, Saad F, Briganti A, Tilki D, Banek S, Mandel P, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Epidemiology of Unconventional Histological Subtypes of Urethral Cancer. *Urol Int*. 2023;107(1):15-22. Epub 2022 Jul 26.
 510. Teglia F, Boffetta P. Association between trends of mortality and incidence, survival and stage at diagnosis for six digestive and respiratory cancers in United States (2009-2013). *Eur J Cancer Prev*. 2023 Mar 1;32(2):195-202. Epub 2022 Jul 19.

511. Plym A, Zhang Y, Stopsack KH, Delcoigne B, Wiklund F, Haiman C, Kenfield SA, Kibel AS, Giovannucci E, Penney KL, Mucci LA. A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer. *Eur Urol.* 2023 Apr;83(4):343-351. Epub 2022 May 28.
512. Ke S, Wang W, Li B, Feng X, Yan D, Liu J. Superior survival for breast-conserving therapy over mastectomy in patients with breast cancer: A population-based SEER database analysis across 30 years. *Front Oncol.* 2023 Jan 4;12:1032063. doi: 10.3389/fonc.2022.1032063. eCollection 2022.
513. Pei J, Shu T, Wu C, Li M, Xu M, Jiang M, Zhu C. Impact of human papillomavirus vaccine on cervical cancer epidemic: Evidence from the surveillance, epidemiology, and end results program. *Front Public Health.* 2023 Jan 6;10:998174. doi: 10.3389/fpubh.2022.998174. eCollection 2022.
514. Zhang H, Ren D, Cheng D, Wang W, Li Y, Wang Y, Lu D, Zhao F. Construction of a mortality risk prediction model for elderly people at risk of lobectomy for NSCLC. *Front Surg.* 2023 Jan 6;9:1055338. doi: 10.3389/fsurg.2022.1055338. eCollection 2022.